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General introduction and outline of this thesis 9
inTroducTion
In 1666 Jean Baptiste Denis for the first time transfused a human being.1 At that time 
lamb blood was used for transfusion, which gave a severe transfusion reaction. Since 
that time much effort has been made to make transfusion as save as it is today. However 
transfusions still presents a risk to the recipient. Probably in the 1950s the first cases of 
transfusion-related acute lung injury (TRALI) were reported in the literature, although 
they were not recognized as a distinct clinical syndrome.2,3 In 1983, over three hundred 
years after the first blood transfusion, Popovsky and coworkers coined the name TRALI 
(Transfusion-related acute lung injury), that implies a serious, sometimes fatal compli-
cation of blood transfusion.4 In 1985 they published the first series of 36 TRALI cases 
from the Mayo Clinic.5 Since 2003 it is the leading cause of transfusion-related mortality 
according to the FDA.6 The diagnosis of TRALI is based on clinical and radiographic find-
ings, there is no pathognomonic laboratory test.
definiTion of Trali
The definition of TRALI proposed in 1985 by Popovsky et al. has changed little since then.5 
TRALI is a clinical diagnosis. In 2004 the Canadian Consensus Conference formulated a 
definition of TRALI based on clinical and radiological findings.7,8 It defined TRALI as a 
new episode of acute lung injury (ALI) that occurs during or within 6 hours of a blood 
transfusion and is not temporally related to another risk factor for ALI. ALI is defined 
as the acute onset of respiratory distress and hypoxemia (PaO2-to-FiO2 ratio less than 
Table 1. Criteria for (possible) TRALI according to the Canadian Consensus Conference
Trali
a. ALI
	 •	 Acute	onset
	 •	 Hypoxemia	(PaO2/FiO2 ≤ 300 mmHg or saturation < 90% on room air)
	 •	 Bilateral	infiltrates	on	chest	radiograph
	 •	 No	evidence	of	left	atrial	hypertension	(i.e.	circulatory	overload)
b. No preexisting ALI before transfusion
c. During or within 6 hours of transfusion
d. No alternative risk factor for ALI present*
possible Trali
a. ALI
b. No preexisting ALI before transfusion
c. During or within 6 hours of transfusion
d. Alternative risk factor for ALI present*
* Risk factors for ALI include sepsis, aspiration, pneumonia, toxic inhalation, lung contusion, near drowning, 
cardiopulmonary bypass, drug overdose.
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300 mm Hg, saturation less than 90% on room air or other clinical evidence), bilateral 
infiltrates on chest X-ray and no evidence of circulatory overload. When ALI is temporally 
related to both transfusion and an alternative risk factor the term “possible TRALI” is 
used (table 1). Other risk factors include for example sepsis, aspiration, pneumonia and 
multiple trauma.
clinical PresenTaTion
TRALI is underdiagnosed and sometimes mistaken for circulatory overload after transfu-
sion or ALI caused by other risk factors. The diagnosis of TRALI is based on clinical findings 
manifested within 6 hours of transfusion of a blood product. Most often it develops well 
before the 6 hours after transfusion, sometimes even during the infusion of the blood 
product. Clinical hallmarks of TRALI include dyspnea, tachypnea, hypoxemia, bilateral 
pulmonary infiltrates on chest X-ray (figure  1) and frothy edema fluid in the endotra-
cheal tube, in the absence of evidence of circulatory overload and cardiac dysfunction.
Also reported are febrile reactions and hypothermia, both hypotension and (rarely) 
hypertension, chills and tachycardia.9-11 In mechanical ventilated patients, the diagnosis 
should be considered whenever there is an acute unexplained worsening in respiratory 
status that is temporally related with a transfusion. Clinical signs in these patients may 
include frothy pink edema in the endotracheal tube, decrease in P/F ratio or increase 
in airway pressures. There are no specific diagnostic tests for TRALI. The differential 
HOOFDSTUK	  1	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure 1. 
	  
	  
figure 1. Bilateral infiltrates on chest X-ray in a patient with TRALI
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diagnosis includes circulatory overload and this has to be excluded. Echocardiography 
and measurement of brain natriuretic peptide (BNP) can be useful in these. Transient 
leukopenia has been temporally associated with the onset of TRALI.11,12
PaThogenesis
leukocyte antibodies
The majority of TRALI cases have been related to HLA- or HNA-antibodies in plasma rich 
transfusion products.13,14 Red blood cell products (RBCs) and platelet transfusion prod-
ucts (PLTs) are produced with small volumes of plasma but can still cause TRALI.15-17A 
correlation between the HLA and HNA antibody strength and development of TRALI 
has been indicated which might explain why also small volumes have been related to 
TRALI.15,18
Based on several retrospective studies HLA-class I antibodies account for 14.3-26.7% of 
TRALI cases, HLA-class II antibodies 0.0-46.7% and HNA 16.7-28.6%.19-26 These numbers 
have to be interpreted with caution as many older studies did not test for HNA-antibody 
prevalence and newer, more sensitive techniques have been developed to detect anti-
bodies.
Threshold model and two hit model
Reported TRALI incidence varies between 0.08-15.1% per patient and 0.01-1.12% 
per product transfused.27 The great variety in incidence suggests not all patients or 
blood products have an equal risk for onset of TRALI. Indeed, studies among critically 
ill patients showed an increased risk for developing TRALI. On the other hand studies 
reported that it is possible to develop TRALI in the absence of any underlying condition 
i.e. (relatively) healthy individuals.28-30 Furthermore, the majority of antibody containing 
blood products do not cause TRALI in all patients20,31-34, even in patients that receive 
blood products with cognate antibodies.8 These observations gave rise to the hypoth-
esis that TRALI follows either a “threshold model” or a “two hit model”. In the “two hit 
model” a “first hit” primes neutrophils and attracts them to the pulmonary vasculature. 
This is followed by a “second hit” that activates these neutrophils with consecutive 
pulmonary damage. Amongst others, haematogical malignancy, cardiovascular disease, 
sepsis and emergency cardiac surgery have been identified as risk factors for a “first hit” 
(figure 2).16,29,35,36 The “second hit” can be formed by HLA- and HNA-antibodies, biologi-
cally active lipids (lysophosphatidylcholines) or other biologic response modifiers (e.g., 
soluble CD40 ligand). In the “threshold model” the threshold is formed by the level of 
priming of lung neutrophils, and the ability of the mediators in the transfusion product 
to activate these primed neutrophils (figure 3).37 Hence, in the “two hit” it is compulsory 
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figure 2. The two hit model of Trali. The “first hit” consists of patient factors, which primes neutrophils 
and attracks them to the lung capillary. The “second hit” is the transfusion of a blood product resulting in 
activation of these primed neutrophils causing pulmonary damage.
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figure 3. The threshold model of TRALI: In the “threshold model” the threshold is formed by the level of 
priming of lung neutrophils (“first hit”), and the ability of the mediators in the transfusion product (“second 
hit”) to activate these primed neutrophils
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to have a “first hit” to develop TRALI which is mainly the case for non-antibody mediated 
TRALI. In the threshold model TRALI may develop in the absence of a “first hit” as long as 
the second hit is strong enough to overcome the threshold. In some TRALI-cases anti-
bodies in the recipient against donor leukocytes have been identified as “second hit” for 
TRALI.22 However after implementation of universal leukoreduction for blood products 
this pathway has become less important.
managemenT
Whenever a TRALI reaction is suspected in a patient, the attending physician should 
report this to the blood bank. Involved donors should be identified and tested for 
leukocyte-reactive antibodies. TRALI is a clinical diagnosis, there is no pathognomonic 
diagnostic test. Many different specialists are involved in the recognition of, and care 
for TRALI patients. Reporting of cases to the blood bank differs between the disci-
plines.38 Also patient factors were reasons for not reporting suspected cases (e.g. sepsis 
before transfusion). Reporting is important because involved donors who have proven 
incompatible antibodies and donors who are associated with a TRALI case two times are 
excluded from further donations to prevent future TRALI reactions in the Netherlands.
TreaTmenT and Prognosis
There is no specific treatment for TRALI. In most cases, TRALI is self-limiting. Management 
of TRALI is supportive. Mild cases need supplemental oxygen only, however 70-90% of 
TRALI cases require mechanical ventilation.5,39,40 In these patients who need mechanical 
ventilation a low tidal volume strategy is recommended, as this is beneficial in patients 
with ALI/acute respiratory distress syndrome and TRALI is considered to be a member 
of these syndromes.15 The use of corticosteroids has never been demonstrated to be 
effective, although some case reports describe the use of these.
Most cases of TRALI are self-limiting and have a good prognosis. The mortality rate of 
TRALI in the general patient population has been reported as 5% to 10%.5,41,42
diagnosTic work-uP of donors
To diagnose antibody-mediated TRALI antibodies directed against recipient’s HNA and/
or HLA antigens have to be detected in the involved blood donor(s). In the evaluation 
of TRALI cases, donors are tested for presence of HNA and HLA-antibodies. There are 
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several techniques to detect these antibodies. These assays are usually only available 
in specialized centres. They are used to confirm antibody mediated TRALI and identify 
donors who pose a potential risk for future patients. As it can take several weeks before 
the results are known, they have no value in diagnosing an acute TRALI-reaction.
hla-antibodies
In 1964 Terasaki and McClelland developed the complement-dependent cytotoxicity 
assay (CDC assay) which has been the golden standard for detecting HLA-antibodies for 
many years.43 Serum to be tested is incubated with HLA-typed donor lymphocytes and 
rabbit complement. If antibodies present in the serum bind to the cognate antigen on 
the lymphocyte, the complement cascade is activated, leading to cell death. By using 
fluorescent dyes cell death was observed using microscopy and used as an indicator 
of the presence of HLA Class I antibodies. The CDC-assay is labour-intensive, requires 
highly skilled staff and fresh preparation of lymphocyte panels of donors with known 
phenotypes.43-45
The CDC was the “gold standard” for years, but most laboratories have replaced it with 
antigen-based assays. These assays use isolated HLA antigens fixed to wells or micro 
beads to detect antibodies.46,47
hna-antibodies
The ISBT Working Party on Granulocyte Immunobiology recommends combining the 
granulocyte immunofluorescence test (GIFT) and the granulocyte agglutination test 
(GAT), both serological methods, to detect HNA-antibodies.48 GIFT is considered to be 
the most sensitive method, but GAT has a better ability to detect HNA-3a antibodies.49
In the GIFT a granulocyte suspension is incubated with serum and FITC-labelled rabbit-
anti-human IgG serum. The product of this assay, a suspension of labelled cells can be 
examined under an immunofluorescence microscope.50 The subjectively observed fluo-
rescence is a measure for antibody activity in the serum. Antibody specificity is assessed 
by testing a panel of neutrophils from donors of known HNA genotypes.
The GAT is performed according to Jiang and Lalezari.51 A granulocyte suspension is 
added to dilutions of test plasma. Cell aggregation and proportion of cells aggregating 
are examined under an inverted phase microscope after which the reaction is graded 
from 0 to 4.
The monoclonal antibody-specific immobilization of granulocyte antigens (MAIGA) is 
another serological method to detect HNA-antibodies.52 The MAIGA is mostly used for 
confirmation of GIFT and GAT results.
These classic, serological methods to identify granulocyte antibodies require daily 
fresh typed granulocytes. The methods are time-consuming and cannot be used for 
detection of neutrophil antibodies in large populations, as for example blood donors. 
Danielle binnenwerk - CP 4.indd   14 30-07-15   12:31
General introduction and outline of this thesis 15
Moreover, the International Granulocyte Immunology Workshop demonstrated that 
there was a wide variation in the proficiency of antibody detection among the differ-
ent laboratories (16.7 – 100% correct detection of antibodies, mean of 57.5%).48 More 
recently analogous to HLA-antibody detection, Luminex bead-based assays have been 
developed to detect HNA-antibodies.53
cross-matching
Cognate antibodies in donors can also be assessed by performing cross-matches be-
tween donor plasma and patient lymphocytes and granulocytes. These cross-matches 
can be performed in the CDC, LIFT, GIFT and GAT.43,50,51 Instead of using typed donor lym-
phocytes or granulocytes in these assays, fresh cells from the patient who experienced 
a TRALI reaction are used and incubated with plasma from the involved donor(s). When 
antibodies directed to HLA or HNA antigens in the patient are present, the cross-match 
will be positive. Cross-matches only identify incompatible antibodies and cross-matches 
can have false negative results. Antigens may have been upregulated during a TRALI 
reaction but cross-matching is usually performed weeks or months after the case is 
reported. Patients have usually recovered by this time and the antigen is downregulated 
again. This may result in a negative cross-match.
PrevenTive measures
Antibody-mediated TRALI caused by the passive infusion of leukocyte-reactive antibod-
ies is considered the most prevalent form of TRALI.5,55 These antibodies develop most 
frequently during pregnancy, when women are exposed to the alloantigens from the 
father. The prevalence of these antibodies increases with each pregnancy, making these 
antibodies most prevalent in multiparous women.56 Other allo-exposed individuals are 
recipients of blood transfusions and organ transplantations.57 After female donors were 
recognized as risk factor for developing TRALI, the United Kingdom implemented a pref-
erentially male donor fresh-frozen plasma strategy in 2003. Several countries followed 
this precautionary measure. Since July 2007 only apheresis plasma from non-transfused 
male donors is used for single-donor FFP in the Netherlands.
Exclusion of all allo-exposed donors leads to exclusion of a very large group of “safe” 
donors, who don’t have these antibodies. To prevent this unnecessary exclusion, allo-
exposed donors could be screened for the presence of HLA and HNA-antibodies.21,58 To 
completely minimize the risk of antibody-mediated TRALI, all donors should be screened 
and all positive donors should be excluded for all blood products containing plasma, 
regardless of the amount of plasma.
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Some countries use pooled solvent/detergent (S/D) plasma instead of single-donor 
fresh-frozen plasma. S/D plasma is plasma pooled from 500-1600 donors. Pooling re-
duces the possible antibody load by dilution. Also the antigens present in the pooled 
plasma might be able to bind the antibodies, causing inactivity of the antibodies.59 In 
2 studies no leukocyte-reactive antibodies were found in units of S/D plasma.59,60 Coun-
tries that use pooled S/D plasma (e.g. Finland, Luxembourg and Norway) have never 
reported TRALI-cases after transfusion of S/D plasma.61
ouTline of The Thesis
The clear association between the presence of donor antibodies and the onset of TRALI 
is the starting point of this thesis. Although the association is acknowledged it is not 
known which donors are at risk to have antibodies. Furthermore current assays for iden-
tification of HLA positive donors have many limitations. Finally strategies aimed at re-
ducing the number of antibody positive donors to prevent the onset of TRALI have been 
introduced however the overall impact has not yet been evaluated. The thesis focuses 
on the role of donor leukocyte-reactive antibodies in TRALI, and the translation to pre-
ventive strategies. In chapter 2, we analyzed all TRALI-cases in the Netherlands reported 
to the Sanquin Blood Bank during a 2.5-year period for patient, donor and product char-
acteristics. All patients and involved donors were screened for anti-leukocyte (HLA and 
HNA) antibodies. In chapter 3 we aimed to examine the relation between female donors 
and the occurrence of TRALI by studying TRALI patients who had received transfusions 
either from female donors or male donors alone. Chapter 4 focuses on the contribu-
tion of alloexposed donors to the occurrence of TRALI for different blood product types 
(plasma-rich and plasma-poor products). Reporting and identifying possible causal 
donors of TRALI cases are keystones in the prevention of future TRALI cases as the impli-
cated donors are excluded from future donations. In chapter 5, we investigated whether 
the use of bead-based techniques might improve the diagnosis of antibody-mediated 
TRALI. We compared cellular-based techniques to bead-based techniques for detection 
of HLA-antibodies in a series of 100 consecutively reported TRALI cases meeting the 
Canadian consensus conference criteria for TRALI. Chapter 6 is a meta-analysis on the 
impact of low risk TRALI donor strategies for plasma containing blood products on the 
onset of TRALI. We performed a meta-analysis of all trials on this topic since 1995. Finally, 
the results are summarized and discussed in chapter 7 (English) and chapter 8 (Dutch).
Danielle binnenwerk - CP 4.indd   16 30-07-15   12:31
General introduction and outline of this thesis 17
reference lisT
 1. Sturgis CC. The history of blood transfusion. Bull Med Libr Assoc. 1942;30(2):105-112.
 2. Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity 
reactions. N Y State J Med. 1951;51(20);2399-2402.
 3. Brittingham TE. Immunologic studies on leukocytes. Vox Sang. 1957;2(4):242-248.
 4. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with the pas-
sive transfer of anti-leukocyte antibodies. Am Rev Respir Dis. 1983;128(1):185-189.
 5. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related 
acute lung injury. Transfusion. 1985;25(6):573-577.
 6. http://www.fda.gov/biologicsbloodvaccines/safetyavailability/reportaproblem/transfusiondo-
nationfatalities/ucm346639.htm. Accessed March 12, 2015
 7. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S et al. Toward an under-
standing of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 
2004;44(12): 1774-1789.
 8. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a 
consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005;19(1):2-31.
 9. Van Stein D, Beckers EA, Sintnicolaas K et al. Transfusion-related acute lung injury reports in the 
Netherlands: an observational study. Transfusion 2010;50(1):213-220.
 10. Vlaar AP, Porcelijn L, van Rooijen-Schreurs IH, Lardy NM, Kersten MJ, Juffermans NP. The divergent 
clinical presentations of transfusion-related acute lung injury illustrated by two case reports. Med 
Sci Monit 2010;16(10):CS129-134.
 11. Fadeyi EA, De los Angeles MM, Wayne AS, Klein HG, Leitman SF, Stroncef DF. The transfusion of 
neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. 
Transfusion 2007;47(3):545-550.
 12. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 
2004;126(1):249-258.
 13. Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A. Transfusion-related acute lung injury 
due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J 
Haematol 1996;93(3): 707-713.
 14. Middelburg RA, van Stein D, Briet E, van der Bom JG. The role of donor antibodies in the pathogen-
esis of transfusion-related acute lung injury: a systemetic review. Transfusion 2008;48(10):2167-
2176.
 15. Toy P, Gajic O, Bacchetti P et al. Transfusion-related acute lung injury: incidence and risk factors. 
Blood 2012;119
 16. Vlaar AP, Hofstra JJ, Determann RM et al.The incidence, risk factors and outcome of transfusion-
related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control 
study. Blood 2011;117(16):4218-4225.
 17. Win N, Chapman CE, Bowles KM et al. How much residual plasma may cause TRALI? Transfus Med 
2008;18(5):276-280.
 18. Hashimoto S, Nakajima F, Kamada H et al. Relationship of donor HLA antibody strength to the 
development of transfusion-related acute lung injury. Transfusion 2010;50(12):2582-2591.
Danielle binnenwerk - CP 4.indd   17 30-07-15   12:31
18 Chapter 1
 19. Chapman CE, Stainsby D, Jones H et al. Ten years of hemovigilance reports of transfusion-related 
acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. 
Transfusion 2009:49(3):440-452.
 20. Fadeyi EA, Adams S, Sheldon S et al. A preliminary comparison of the prevalence of transfusion 
reactions in recipients of platelet components from donors with and without human leucocyte 
antigen antibodies. Vox Sang 2008;94(4):324-328.
 21. Funk MB, Guenay S, Lohmann A et al. Benefit of transfusion-related acute lung injury risk-minimi-
zation measures—German haemovigilance data (2006-2010). Vox Sang 2012;102(4):317-323.
 22. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of 
antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion 2003;43(2):177-
184.
 23. Porretti L, Cattane A, Coluccio E et al. Implementation and outcomes of a transfusion-related 
acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood 
donors. Blood Transfus 2012;10(3):351-359.
 24. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-
related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 
2008;95(4):313-317.
 25. Sachs UJ, Link E, Hofmann C, Wasel W, Bein G. Screening of multiparous women to avoid transfu-
sion-related acute lung injury: a single centre experience. Transfus Med 2008;18(6):348-354.
 26. Zupanska B, Uhrynowska M, Michur H, Maslanka K, Zajko M. Transfusion-related acute lung injury 
and leucocyte-reacting antibodies. Vox Sang 2007;93(1):70-77.
 27. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. The Lancet 
2013;382(9896):984-994.
 28. Engelfriet CP, Reesink HW. Transfusion-related acute lung injury (TRALI). Vox Sang 2001;81(4):269-
270.
 29. Gajic O, Rana R, Winters JL et al. Transfusion-related acute lung injury in the critically ill: prospec-
tive nested case-control study. Am J Respir Crit Care Med 2007;176(9):886-891.
 30. Toy P, Popovsky MA, Abraham E et al.Transfusion-related acute lung injury: Definition and review. 
Crit Care Med 2005;33(4):721-726.
 31. Nicolle AL, Chapman CE, Carter V, Wallis JP. Transfusion-related acute lung injury caused by two 
donors with anti-human leucocyte antigen class II antibodies: a look-back investigation. Transfus 
Med 2004;14(3):225-230.
 32. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA an-
tibodies: a lookback study of transfusion-related acute lung injury. Transfusion 2004;44(12):1683-
1688.
 33. Maslanka K, Michur H, Zupansk B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors 
and a look back on recipients of their blood components. Vox Sang 2007;92(3):247-249.
 34. Powers A, Stowell CP, DzikWH, Saidman SL, Lee H, Makar RS. Testing only donors with a prior 
history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung 
injury prevention strategy. Transfusion 2008;48(12):2549-2558.
 35. Rana R, Fernandez-Perez ER, Khan SA et al. Transfusion-related acute lung injury and pulmonary 
edema in critically ill patients: a retrospective study. Transfusion 2006;46(9):1478-1483.
Danielle binnenwerk - CP 4.indd   18 30-07-15   12:31
General introduction and outline of this thesis 19
 36. Silliman CC, Boshkov LK, Mehdizadehkashi Z et al. Transfusion-related acute lung injury: epidemi-
ology and a prospective analysis of etiologic factors. Blood 2003;101(2):454-462.
 37. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 
2007;136(6):788-799.
 38. Vlaar AP, Wortel K, Binnekade JM et al. The practice of reporting transfusion-related acute lung 
injury: a national survey among clinical and preclinical disciplines. Transfusion 2010;50(2):443-
451.
 39. Wallis JP, Lubenko A, Wells AW, Chapman CE. Single hospital experience of TRALI. Transfusion 
2003;43(8):1053-1059.
 40. Looney MR, Roubinian M, Gajic O et al. Prospective study on the clinical course and outcomes of 
transfusion-related acute lung injury. Crit Care Med 2014;42(7):1676-1687.
 41. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as 
compared with traditional tidal volumes for acute lung injury and the acute respiratory distress 
syndrome. N Engl J Med 2000;342(18):1301-1308.
 42. Moore SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment and 
prognosis. Crit Care Med 2006; 34(5 Suppl):S114-117.
 43. Terasaki PI, McClelland JD. Microdroplet Assay of Human Serum Cytotoxins. Nature 1964;204:998-
1000.
 44. Bray RA, Tarsitani C, Gebel HM, Lee JH. Clinical cytometry and progress in HLA antibody detection. 
Methods Cell Biol 2011;103:285-310.
 45. Stroncek DF, Fadeyi E, Adams S. Leukocyte antigen and antibody detection assays: tools for as-
sessing and preventing pulmonary transfusion reactions. Transfus Med Rev 2007;21(4):273-286.
 46. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads 
for accurate identification of human leukocyte antigen antibody specificities. Transplantation 
2003;75(1):43-49.
 47. Pei R, Wang G, Tarsitani C et al. Simultaneous HLA Class I and Class II antibodies screening with 
flow cytometry. Hum Immunol 1998;59(5):313-322.
 48. Lucas G, Rogers S, de Haas M, Porcelijn L, Bux J. Report on the Fourth International Granulocyte 
Immunology Workshop: progress toward quality assessment. Transfusion 2002;42(4):462-468.
 49. Bux J, Chapman J. Report on the second international granulocyte serology workshop. Transfu-
sion 1997;37(9):977-983.
 50. Verheugt FW, von dem Borne AE, Decary F, Engelfriet CP. The detection of granulocyte alloanti-
bodies with an indirect immunofluorescence test. Br J Haematol 1977;36(4):533-544.
 51. Jiang AF, Lalezari P. A micro-technique for detection of leukocyte agglutinins. J Immunol Methods 
1975;7(1):103-108.
 52. Bux J, Kober B, Kiefel V, Mueller-Eckhardt C. Analysis of granulocyte-reactive antibodies using 
an immunoassay based upon monoclonal-antibody-specific immobilization of granulocyte 
antigens. Transfus Med 1993;3(2):157-162.
 53. Fromont P, Prie N, Simon P et al. Granulocyte antibody screening: evaluation of a bead-based 
assay in comparison with classical methods. Transfusion 2010;50(12):2643-2648.
Danielle binnenwerk - CP 4.indd   19 30-07-15   12:31
20 Chapter 1
 54. Greinacher A, Wesche J, Hammer E. Characterization of the human neutrophil alloantigen-3a. Nat 
Med 2010;16(1):45-48.
 55. Curtis BR, McFarland JG. Mechanisms of transfusion-related acute lung injury (TRALI): anti-
leukocyte antibodies. Crit Care Med 2006;34(5 Suppl):S118-123.
 56. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female 
apheresis donors. Transfusion 1999;39(1):103-106.
 57. Triulzi DJ, Kleinman S, Kakaiya RM et al. The effect of previous pregnancy and transfusion on HLA 
alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk 
reduction strategy. Transfusion 2009;49(9):1825-1835.
 58. Lucas G, Win N, Calvert A et al. Reducing the incidence of TRALI in the UK: the results of screen-
ing for donor leucocyte antibodies and the development of national guidelines. Vox Sang 
2012;103(1):10-17.
 59. Sachs UJH, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/
detergent plasma. Transfusion 2005;5(10):1628-1631.
 60. Sinnott P, Bodger S, Gupta A, Brophy M. Presence of HLA antibodies in single-donor-derived 
fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J 
Immunogenet 2004;31(6):271-274.
 61. Schmickl CN, Mastrobuoni S, Filippidis FT et al Male-predominant plasma transfusion strat-
egy for preventing transfusion-related acute lung injury: a systematic review. Crit Care Med 
2015;43(1):205-225.
Danielle binnenwerk - CP 4.indd   20 30-07-15   12:31
Danielle binnenwerk - CP 4.indd   21 30-07-15   12:31
Danielle binnenwerk - CP 4.indd   22 30-07-15   12:31
2 
Transfusion-related acute 
lung injury reports in 
the Netherlands: 
an observational study
Daniëlle van Stein, Erik A. Beckers, Kees Sintnicolaas, 
Leendert Porcelijn, Fikreta Danovic, 
Jacques A. Wollersheim, Anneke Brand, and
 Dick J. van Rhenen
Transfusion 2010;50:213-220
Danielle binnenwerk - CP 4.indd   23 30-07-15   12:31
24 Chapter 2
absTracT
background
Transfusion-related acute lung injury (TRALI) is a serious, sometimes fatal complication 
of transfusion, attributed to white blood cell (WBC)-reactive antibodies present in the 
blood product. This study investigated incidence and etiology in the Netherlands.
study design and methods
From January 2005 through July 2007, all TRALI cases reported to the Sanquin Blood 
Banks were evaluated. Only cases meeting the Canadian Consensus Conference criteria 
for TRALI were included and investigated for patient, donor, and product characteristics. 
Patients and donors were screened for HLA class I, HLA class II and granulocyte antibod-
ies.
results
A total of 56 TRALI cases were reported of which 49 were completely evaluated. Seventy-
eight percent of the patients needed monitoring or mechanical ventilation on the 
intensive care unit, 10 patients died. In 61% of cases large-volume plasma products were 
involved. WBC-reactive antibodies in donors were found in 73% of cases, with proven 
incompatibility in 21 out of 44 (48%) investigated cases. Possible TRALI cases, as defined 
by Canadian Consensus Conference, had statistically significant lower incompatibility 
rates compared to TRALI cases, 18% vs. 58% (p=0.036). In the 21 alloimmune cases, a 
total of 31 implicated donors were found, of which 26 were female, including 12 fresh-
frozen plasma (FFP) products.
conclusion
TRALI is the most serious transfusion complication in the Netherlands, causing severe 
morbidity and mortality. Antibodies were found in the majority of the cases, but cau-
sality with proven incompatibility could be established in 21 cases ( 48%). Female FFP 
products were involved in 57% of proven alloimmune cases and would theoretically be 
prevented using male FFP only.
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inTroducTion
Transfusion-related acute lung injury (TRALI) is a serious, possibly fatal complication 
of blood transfusion. It is now the leading cause of transfusion-associated mortality 
according to the FDA.1 TRALI is diagnosed based on clinical and radiographic findings 
and is defined as a new episode of acute lung injury (ALI) occurring during or within 6 
hours of a blood transfusion.2 The exact pathogenesis of TRALI is not fully elucidated 
yet. There are two proposed mechanisms: The antibody-mediated mechanism and the 
two-event model.3,4 Although it is increasingly recognized in recent years, there still is 
a lack of clinical recognition of TRALI, which leads to misdiagnosis and underreporting. 
Although numerous case reports have been documented in the literature, only a few 
case series have been published. The definition used for TRALI differed between these 
studies. TRALI incidence reportedly ranges from 1 in 432 to 1 in 5000 blood products.5,6
This observational study describes the clinical and laboratory features of all reported 
TRALI cases in the Netherlands in a 2.5-year period. The occurrence of TRALI cases in the 
Netherlands, where all red blood cell (RBC) units and half of PLT units have low plasma 
volumes (less than 30 ml) and where a prestorage leukoreduction policy was imple-
mented in 2002, was not known and might be different from other countries, where 
PLTs with high plasma volumes (more than 100 ml) or leukoreduction is not in place.
We adhered strictly to the Canadian consensus criteria and used an extensive diag-
nostic package for screening patients and all involved donors for HLA class I, HLA class II, 
and granulocyte-specific antibodies. Participating in an active hemovigilance program, 
a relatively large number of 49 TRALI cases, which represents one of the largest TRALI 
series, was included and analyzed for patient, donor, and product characteristics.
maTerials and meThods
Patient study population
All suspected cases of TRALI in the Netherlands reported to the Sanquin Blood Banks 
during a 2.5-year period (January 2005-July 2007) were evaluated. TRALI was diagnosed 
by the hospital medical personnel and subsequently reported to one of the transfusion 
consultants of the blood bank. The Sanquin Blood Bank is divided into four regions, each 
serving a quarter of the population of the Netherlands. Patients were included from all 
four blood bank regions. All cases of TRALI were reviewed by one of us (DS, EB, FD, and 
JW). We followed the consensus criteria for TRALI from the Canadian Consensus confer-
ence (Table 1).2,7 Only cases meeting these criteria were included and investigated for 
patient, donor, and product characteristics.
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Patient characteristics collected include age, sex, admitting diagnosis, transfused 
blood components, and clinical manifestations. All donors of blood products transfused 
within 6 hours before the development of TRALI were investigated, and donor variables 
reviewed included sex, age, parity, blood transfusions in past, and results of antibody 
testing. A donor involved in a TRALI case was designated as implicated when incompat-
ibility was proven between donor antibodies and patient cells. When antibodies were 
not incompatible with patient antigens or in absence of these antibodies, the donor was 
flagged as associated with a TRALI case.
blood products
The patients were transfused with RBCs, PLTs, or fresh frozen plasma (FFP). The RBCs were 
suspended in saline-adenine-glucose-mannitol additive solution (AS) and prestorage 
leukoreduced (< 1 x 106 white blood cells [WBCs]). The final product contained a mean 
volume of 20 mL of plasma, the mean total volume was 270 mL, and the mean hae-
matocrite 0.57 L/L. The majority of PLT products transfused were pooled random-donor 
units (prepared from the buffy coats [BCs] of five donors). Pooled PLTs were prestorage 
leukoreduced (< 1 x 106 WBCs) and suspended in plasma or PLT AS (PAS II). The mean 
volume was 310 mL. Single-donor apheresis units were only used when HLA-compatible 
PLTs were needed. When indicated, RBCs and PLTs were washed or irradiated. FFP is 
derived from single-donor apheresis donations and contains fewer than 1 x 106 WBCs. 
The plasma is quarantined for at least 6 months. The volume was approximately 325 mL. 
For all patients, type and storage time of the blood products transfused within 6 hours 
before the development of signs and symptoms were recorded.
Table 1. Criteria for TRALI and possible TRALI from the Canadian Consensus Conference2
Trali
a. ALI
	 •	 Acute	onset
	 •	 Hypoxemia	(PaO2/FiO2 ≤ 300 mmHg or saturation < 90% on room air)
	 •	 Bilateral	infiltrates	on	chest	radiograph
	 •	 No	evidence	of	left	atrial	hypertension	(i.e.	circulatory	overload)
b. No preexisting ALI before transfusion
c. During or within 6 hours of transfusion
d. No alternative risk factor for ALI present*
possible Trali
c. ALI
d. No preexisting ALI before transfusion
c. During or within 6 hours of transfusion
d. Alternative risk factor for ALI present*
* Risk factors for ALI include sepsis, aspiration, pneumonia, toxic inhalation, lung contusion, near drowning, 
multiple trauma, burn injury, acute pancreatitis, cardiopulmonary bypass, drug overdose.
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laboratory tests
WBC-reactive antibodies were examined in all patients (in posttransfusion blood sam-
ples and, if available, in pre-transfusion samples) and in all donors of blood components 
transfused to patients within 6 hours preceding the development of TRALI.
All patients and donors were screened for HLA antibodies using a standard 
complement-dependent cytotoxicity (CDC) assay against a panel of HLA class I-typed 
donor lymphocytes, to detect complement-fixing antibodies to HLA Class I, and using 
a two-colored fluorescence test with a panel of HLA class II-typed donor B lymphocytes 
for the detection of HLA Class II antibodies. In addition, a flow cytometry bead-based 
screening assay for the presence of HLA Class I and II antibodies (FlowPRA, One Lambda, 
Inc., Canoga Park, CA) was used.8
If samples were positive by CDC and/or flow cytometry screening assay, the specific-
ity of HLA Class I and II antibodies was determined using single antigen beads on the 
Luminex platform (Labscreen SA, One Lambda, Inc. ). A cutoff for a positive Luminex 
test of 1000 (normalized) mean fluorescence intensity was used. Lymphocyte-reactive 
antibodies were examined by the lymphocyte immunofluorescence test (LIFT) against 
two pools of five typed donor-lymphocyte suspensions each, according to Décary et 
al.9 Granulocyte-specific antibodies were examined by the granulocyte immunofluo-
rescence test (GIFT; HNA-1a, -1b, -1c, and -2a) based on the method of Verheugt and 
coworkers10 and by the granulocyte agglutination technique for HNA-3a, according to 
Jiang and Lalezari.11
The patients and when appropriate (in case of specific patient antibodies) also do-
nors were phenotyped in the GIFT for HNA-1a, 1b, 2a, and 3a and genotyped by using 
a polymerase chain reaction-based assay with sequence-specific primers (Olerup SSP 
AB, Saltsjöbaden, Sweden) and/or sequence-specific oligonucleotides primers (One 
Lambda, Inc.) for HLA Class I and II. WBC incompatibility was also assessed by perform-
ing cross-matches between donor serum and patient’s lymphocytes and granulocytes 
in the CDC, LIFT, GIFT and granulocyte agglutination technique. Donors were assigned 
incompatible if either a positive cross-match or specific antibodies against cognate 
antigens in the patient were found.
statistics
Statistical analysis was performed with computer software (SPSS 15.0 for Windows, SPSS, 
Inc. Chicago, IL). Frequencies were described as mean, median, and range. Statistical 
differences between the TRALI and possible TRALI group were tested with the Fisher’s 
exact test. p Values less than 0.05 were considered significant.
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resulTs
recipients
Fifty-six cases of suspected TRALI were reported to the Sanquin Blood Banks in the 2.5-
year period. Forty-nine cases were completely evaluated and met all criteria for TRALI. In 
four cases another diagnosis was more likely to have caused the symptoms (circulatory 
overload, pulmonary embolism) and from three patients additional information was 
insufficient for a definitive diagnosis. In 2005, 13 reports; in 2006, 24; and in the first 
half of 2007, 12 reports met the TRALI criteria. Of these 49 cases 24 (49%) were females. 
The mean age of the recipients was 52.6 years, with a range of 5 to 81 years (median, 59 
years; Table 2).
The most commonly reported clinical signs and symptoms of TRALI were hypoxemia 
and pulmonary infiltrates on chest X-ray (both required to meet the criteria for TRALI), 
shortness of breath, frothy sputum from endotracheal tube, hypotension and fever. 
Various admitting diagnoses were reported. Of all patients 26 were classified as surgical 
and 23 as nonsurgical. In the nonsurgical group, 11 patients were diagnosed with hema-
tologic disorders (of which 9 were malignant), and 5 patients had an (active) infection 
Table 2. Characteristics of TRALI/possible TRALI patients
Patients n=49 (%)
Age mean 52.6
 Median 59 
 Range 5-81 
Male:female 25:24
Diagnosis
 Surgical 26 (53%) 
 Non-surgical 23 (47%) 
Ventilated during transfusion/start of symptoms 11 (22%)
After transfusion: Mechanical ventilation 21 (55%)
 Non-invasive ventilation 2 (5%) 
 Supplemental oxygen 15 (39%) 
Fever 14/43 (33%)*
Chills 4/42 (10%)*
Cyanosis 9/36 (25%)*
Hypotension 13/41 (32%)*
Frothy sputum from endotracheal tube* 10/18 (56%)†
* information was not available for all cases
† 17 patients were not intubated during or after the start of the symptoms; in 14 cases
no information was available.
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(e.g., pancreatitis, pneumonia). Eleven patients were already on mechanical ventilation 
during transfusion or at the start of the signs and symptoms. Of the other 38 patients, 
21 (55%) required mechanical ventilation after the onset of the TRALI; the remainder 
needed supplemental oxygen (Table 2). In 11 patients (22%) an alternative risk factor 
for ALI was present: 4x sepsis, 3x pneumonia, 1x multiple trauma, 1x cardiopulmonary 
bypass, 1x acute pancreatitis, and 1x circulatory overload. Four patients were already in 
the intensive care unit (ICU); 76% (34/45) of the remaining patients were transferred to 
the ICU. Ten (20%) TRALI patients died; in seven patients the TRALI reaction contributed 
significantly to the patients’ death. In the other three cases it remained obscure whether 
TRALI was a contributing factor in the cause of death.
associated blood products
Table 3 lists the characteristics of the involved blood products and donors involved in 
the 49 cases. The patients received a mean of 4.2 blood products in the 6-hour period 
before the beginning of the TRALI reaction (median, 3; range 1-17). In 30 of 49 (61%) 
cases, high-volume plasma products (FFP and/or PLTs) were involved; in 39% of the 
cases the patient only received RBCs. The mean age of the transfused RBCs and PLTs was 
17 (range, 6-34; median, 17) and 4.7 (range, 2-7; median, 5) days, respectively.
Table 3. Involved blood products and donors
involved blood products cases
RBCs 19 (39%)
FFP 3 (6%) 
PLTs in plasma 2 (4%) 
RBCs plus FFP 17 (35%) 
RBCs plus PLTs in plasma 4 (8%) 
RBCs plus FFP plus PLTs (PAS/plasma) 4 (8%) 
number of blood products
Mean 4.2 
Median 3 
Range 1-17 
involved donors
Total number 259 
Mean 5.3 
Male : female 156 : 103 
RBC number 129 (78 male : 51 female)
BC number 66 (41 male : 25 female) 
FFP number 64 (37 male : 27 female) 
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donors
The 49 patients received blood products from 259 donors, with a mean number of 
donors of 5.3 per case (median, 4; range, 1-17; Table 3). The male : female ratio was 157: 
102 (61%: 39%) and represented the ratio of blood products stored at the blood bank 
facilities. The mean age of the donors at time of donation of the involved blood product 
was 46.9 years (range, 18-69; median, 49 years). Parity information was provided for 94 
female donors. Of these 94 donors, 70 donors have been pregnant at least one time 
(mean, 2.6 pregnancies; median, 2; range, 1-7) and 24 donors have never been pregnant. 
Seven donors (five women and two men) had a past history of blood transfusion. Two 
female plasma donors were two times involved in a TRALI case.
laboratory test results
Patients
Forty-three patients were tested for HLA- and granulocyte-reactive antibodies; 18 (42%) 
tested positive, of which 11 were female and seven were male. In six cases only patient 
antibodies were found; in the other 12 cases at least one of the involved donors also 
tested positive for antibodies.
In nine cases HLA Class I and in two cases a combination of HLA Class I and II anti-
bodies were found. HNA antibodies were found in two patients and five patients had 
nonspecific WBC-reactive antibodies (positive screening in the LIFT and/or CDC).
Donors
In 36 cases antibodies were detected in at least one of the involved donors (Table 4). 
In 24 of these cases, the antibodies were found in the donors of the transfused blood 
Table 4. Antibody and incompatibility testing in involved donors and products
donor 
antibodies
cases with
donor antibodies
antibodies in donors
number male female
involved products
from male donors
involved products
from female donors
Incompatible 21 31* 6 25
4 RBCs
2 FFP
10 RBCs
3 BCs
12 FFP
Compatible 10 13* 6 7
5 RBCs
1 FFP
2 RBCs
3 BCs
2 FFP
Compatibility 
not tested
5 11* 6 5
4 RBCs
2 FFP
2 RBCs
1 BCs
2 FFP
All donors 36 55* 18 37
13 RBCs
5 FFP
14 RBCs
7 BCs
16 FFP
* In some cases antibodies were found in more than one donor
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product only; in the other 12 cases antibodies were found in both the donor(s) and the 
recipient. The specificities of donor antibodies are listed in Table 5.
Incompatibility testing
In 31 cases of the 36 cases with donor antibodies, compatibility testing was performed. 
In the remaining five cases blood samples for performing cross-matches or DNA typing 
were not obtained, because either the patient had died or the patient was not trace-
able anymore. Incompatible donor antibodies were present in 21 (68%) of these cases 
(Table 4). In two additional cases (with no detectable donor antibodies) patient antibod-
ies were found incompatible with at least one of the involved donors (data not shown).
In 15 cases there was one implicated donor; in, respectively, three, two, and one 
case(s) there were two, three, and four donors with incompatible antibodies. In all 21 
cases with proven incompatible donor antibodies, a total of 31 donors were involved, 
of which 25 (81%) were female. Fourteen of the 31 products with incompatible donor 
antibodies appeared to be FFP. Of these, 12 (86%) were from female donors (Table 4). 
The incompatibility rate was higher in TRALI without risk factors for ALI, compared to 
TRALI in presence of a risk factor (possible TRALI), and appeared statistically significant 
(58%% vs. 18%, p= 0,036; Table 6). In cases in which only RBCs were used, the incompat-
Table 5. Specificity of donor antibodies (36 cases)
incompatible compatible incompatibility not tested Total
HLA Class I antibodies 4 5 2 11
HLA Class II 3 1 0 4 
HLA Class I and II 9 1 2 12 
HLA Class I and HNA 3 0 1 4 
HNA 1 0 0 1 
IgM 1 3 0 4 
Total 21 10 5 36 
Table 6. Antibody and incompatibility testing in cases
Cases Total Possible Trali Trali rbc only Plus ffP Plus PlT
All cases 49 11 38 19 24 6
Cases with donor antibodies 36 7 29 10 23 3 
Compatibility tested  
(in presence of donor antibodies) 
31 7 24 8 21 2 
Proven incompatibility 21 2* 19* 3 18 0 
In presence of patient antibodies 10 2 8    
* statistically significant: p=0.036
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ibility rate was also significantly lower than in cases with high-volume plasma products 
(3/17=18% vs. 18/22=82%, p<0.0005; Table 6).
discussion
The name TRALI was first coined by Popovsky and coworkers in 1983.12 In 1985 they 
published the first series of 36 TRALI cases from the Mayo Clinic.5 The diagnosis of TRALI 
is based on clinical and radiographic findings, because there is no pathognomonic labo-
ratory test for TRALI. In 2004 the Canadian Consensus Conference defined TRALI2,7 as a 
new episode of ALI that occurs during or within 6 hours of a blood transfusion and is 
not temporally related to another risk factor for ALI. ALI is defined as the acute onset of 
respiratory distress and hypoxemia (PaO₂-to-FiO₂ ratio of less than 300 mm Hg, satura-
tion less than 90% on room air or other clinical evidence), bilateral infiltrates on chest 
X-ray, and no evidence of circulatory overload.6 When ALI is temporally related to both 
transfusion and an alternative risk factor the term “possible TRALI” is used. Here, we 
describe all and only TRALI cases fulfilling these consensus criteria that were reported 
to the Sanquin Blood Banks during a 2.5 year period. Nationwide 49 TRALI reports were 
thoroughly studied. During the study period, an increase in reports was noticed, from 
six in the first half of 2005 to 12 reports in the first half of 2007, indicating a greater 
awareness of TRALI.
The incidence of TRALI reported in the literature ranges from 1 in 11206 to 1 in 50005 
for all blood components and up to 1 in 432 per unit of platelets6. In 2006 a total of 
700,758 blood products (556,509 RBC, 51,869 PLT and 92,380 FFP units) were issued 
by the Sanquin Blood Banks to Dutch hospitals. In that year, 24 TRALI reactions were 
reported, giving an estimated frequency in the Netherlands of approximately 1 in 29,000 
(0,003%), which is lower than what was expected from the literature. This difference 
might be explained by the use of different definitions for TRALI between studies. We 
have stringently held on to the Canadian Consensus Conference criteria, which require, 
among other things, a chest X-ray. Milder TRALI cases, in which no chest radiographs 
were made, might have been missed or excluded in this way.
The types of blood products used in different countries are not always comparable 
and may not hold the same risk for TRALI. Leukoreduced (RBC, FFP, and PLTs) and plasma-
poor (all RBC and 50% of PLTs) blood products are used in the Netherlands. Possibly 
these products hold a lower risk for TRALI. Also, it should be kept in mind that this ob-
servational study was not designed for true incidence measurement. During this study 
awareness of TRALI increased giving a rise in reported cases, but there probably still is 
underreporting, especially in circumstances in which an alternative risk factor for ALI 
was present. Presumably TRALI is also mistakenly taken for fluid overload in some cases.
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TRALI is a serious event; in this study 78% of the patients needed monitoring and/
or mechanical ventilation in the ICU, and 10 (20%) patients died. These high morbidity 
and mortality rates indicate that TRALI is the number one severe transfusion reaction in 
the Netherlands and the leading cause of transfusion-related deaths. The mortality rate 
of TRALI patients has been reported as 5-10%.5,13 The strict adherence to the Canadian 
Consensus Conference criteria, which might apply to only the more severe and life-
threatening cases of TRALI, and not to the milder, less fatal cases, might possibly explain 
the higher mortality in our study.
The pathogenesis of TRALI is not fully elucidated yet. The majority of cases of TRALI are 
thought to be caused by WBC-reactive antibodies present in the blood product, mainly 
found in (multiparous) female donors. Antibodies against HLA and neutrophil antigens 
were shown to bind to their cognate antigens on neutrophils, causing activation of 
these neutrophils, which then sequestrate in the lungs, causing endothelial damage, 
capillary leakage, and finally pulmonary edema.3 The relevance of these antibodies in 
the pathogenesis of TRALI was shown in an ex vivo rabbit model and an ex vivo rat lung 
model.14,15 However, only a few studies attempted to correlate antibodies in the donor 
with antigens in the patient. They demonstrated incompatibility in 59% to 87.5%5,16-18. 
Two of these studies had only small numbers of TRALI cases. 16,17 Reported incidences of 
WBC-reactive antibodies in TRALI cases (in donor and/or patient) ranged from 25% to 
89%.5,6,13,19 The prevalence of HLA antibodies in the donor population is 2.3% for males 
and 17% for females.20,21 Using these prevalences, we calculated a 37% a priori chance of 
a random patient in our series to receive at least one blood product from a donor with 
HLA antibodies, assuming the patient received blood from 5.3 donors with an equal 
male-to-female ratio to that found in the TRALI cases. In fact, we found WBC-reactive 
antibodies (mainly HLA antibodies) in at least one of the involved donors in 73% (36/49) 
of the TRALI cases.
Although we also tested TRALI patients for the presence of WBC-reactive alloantibod-
ies, their significance in the pathophysiology remains to be elucidated. In two cases, in 
which donor antibodies were not detected, patient alloantibodies were shown to be 
incompatible with at least one of the involved donors. The first of these patients received 
2 RBC units, and the other 1 RBC unit and 1 PLT concentrate. All blood products were 
leukoreduced. In leukoreduced blood products fewer than 1x106 WBCs are present. The 
minimum amount of neutrophils required to be activated to cause sufficient oxidative 
injury to lung endothelium is not known. Whether or not leukoreduction might have 
failed in one of the involved blood products or a possible causative role for soluble HLA 
antigens present in the blood products remain speculative.
In 36 cases antibodies were found in one or more of the involved donors. Incom-
patibility testing was performed in 31 of 36 cases and the presence of incompatible 
antibodies was proven in 21 cases, either by positive cross-match or by identifying the 
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cognate antigen by genotyping. In our series a total incompatibility rate of 48% of cases 
(21/44, five cases not tested) was found. In an additional 10 cases (23%) compatible 
donor antibodies were found.
 In 12 of 21 of the TRALI cases with proven incompatibility (alloimmune TRALI), HLA 
Class II antibodies, either alone or in combination with HLA Class I antibodies, were 
detected, suggesting a more prominent role of donor HLA Class II antibodies in the 
pathogenesis (Table 5). It has been shown that resting neutrophils do not express HLA 
Class II antigens and that activation of neutrophils is mediated via monocytes, which 
are rich in HLA Class II antigens.16 Although the role of antibodies against HLA Class I 
antigens in neutrophil activation has been established, a dilutional effect is expected, as 
HLA antigens are also expressed on other cells.
 Another pathophysiological hypothesis is the two-event model. The first event is 
related to the underlying clinical condition of the patient (e.g., infection or surgery) 
that causes activation of the pulmonary endothelium, leading to the sequestration and 
priming of neutrophils to the activated endothelium. Transfusion is the second event: 
transfused WBC-reactive antibodies, biologically active lipids (lysophosphatidylcho-
lines), and/or other biological response modifiers (e.g., soluble CD40 ligand) activate 
the primed neutrophils, causing endothelial damage and subsequently TRALI.4,22 These 
lipids and biological response modifiers accumulate during storage of blood products, 
suggesting that older blood products are more prone to cause TRALI.23,24 In 13 of our 
cases we did not find WBC-reactive antibodies in donors and in 10 other cases com-
patible donor antibodies were found, together representing 52% of cases (23/44, five 
not tested). Biologically active lipids or other biological response modifiers might have 
caused these TRALI reactions. Differences in product storage times between the allo-
immune and nonalloimmune TRALI cases were not found (data not shown). However, 
because most of the patients received more than 1 product (mean, 4.2 products), the 
causal products could not be identified, which leaves this question unresolved.
Clinically, two distinct groups were identified: the TRALI group with no alternative risk 
factor for ALI and the possible TRALI group with another risk factor for ALI present. In 
the TRALI group incompatibility was shown in 19 of 33 tested cases (58%). In the pos-
sible TRALI group, incompatible antibodies were found in 2/11 (18%) cases (Table 6). The 
difference between these two groups was significant (p=0.036). It may be argued that 
some cases of possible TRALI are actually not transfusion related but are ALI caused by 
another risk factor, for example, sepsis or pneumonia. It is also possible that indeed a 
different, non-immune mechanism underlies the pathogenesis of these possible TRALI 
cases, as was postulated in the two-event hypothesis.
Since July 2007, as a precautionary measure against TRALI, only apheresis plasma from 
nontransfused male donors is used for single-donor FFP in the Netherlands. In 19 of 49 
TRALI cases in this study, at least one of the blood products was a female FFP. In 12 of 
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these cases incompatibility was proven, indicating that, in retrospect, 12 of 21 (57%) al-
loimmune TRALI cases might theoretically have been prevented with this precautionary 
measure.
Of the 10 patients who died, seven patients received only RBCs and three patients 
were transfused with female FFPs. All three female FFPs contained antibodies: one 
proven incompatible, one compatible, and one not tested. Therefore, at least one death 
(and possibly two; the not tested involved FFP contained a wide variety of antibodies 
against HLA Class I antigens) might theoretically have been avoided, if the preventive 
measure had already been effective. If the preventive measure would also be applicable 
to female-derived BCs used for pooled PLTs, a third case of a TRALI -associated death 
might have been prevented. In this case, two female BCs contained incompatible anti-
bodies, against HLA I /II and HLA I/II and HNA, respectively.
The next few years will prove whether this male-only FFP measure will actually give 
a decline in TRALI cases. SHOT reports indicated a decrease in TRALI cases after the 
introduction of the use of predominantly male plasma for transfusion. However, in the 
SHOT classification of TRALI, nonalloimmune cases are regarded as unlikely and are not 
taken into account.
In conclusion, TRALI is the most serious transfusion complication in the Netherlands, 
causing severe morbidity and mortality. In 73% of the 49 cases fulfilling the Canadian 
Consensus Conference criteria, WBC-reactive donor antibodies were found. Incompat-
ibility was proven in 48% of the cases. The antibodies most frequently found were 
HLA Class I and/or II antibodies. Female FFP was the most frequently implicated blood 
product. Fifty-seven percent of the alloimmune TRALI cases might theoretically have 
been prevented with the male-only FFP measure. We aim to investigate prospectively 
the effect of this precautionary measure, irrespective of the presence of WBC-reactive 
antibodies, in the next year after the introduction.
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absTracT
background
Although quantitative evidence is lacking, it is generally believed that the majority of 
cases of transfusion-related acute lung injury (TRALI) are caused by female blood donors. 
We aimed to examine the relation between female donors and the occurrence of TRALI.
study design and methods
We performed an international, multi-center case-referent study. TRALI patients who 
were diagnosed clinically, independent of serology or donor sex, and had received 
transfusions either only from male donors or only from female donors (Unisex cases) 
were selected. The observed sex distribution among the donors of these TRALI patients 
was compared to the expected sex distribution, based on the relevant donor popula-
tions.
results
83 clinical TRALI cases were included; 67 cases received only red cells, 13 only plasma 
rich products and 3 both. Among red cell recipients the relative risk of TRALI after a 
transfusion from a female donor was 1.2 (95% confidence interval: 0.69 to 2.1) and 
among plasma rich product recipients the RR was 19 (1.9 to 191). The p-value for the 
difference between red cells and plasma was 0.023.
conclusion
Our data support the notion that plasma from female donors is associated with an 
increased risk of TRALI, while red cells from female donors are not.
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inTroducTion
Transfusion-related acute lung injury (TRALI) is currently recognized as the most impor-
tant of the severe side effects of transfusions.1-4 TRALI is characterized by the develop-
ment of acute respiratory distress within six hours after the end of a transfusion, in the 
absence of circulatory overload.5,6 It is clinically indistinguishable from acute respiratory 
distress syndrome (ARDS), but it is rarer and has a better prognosis. The estimated inci-
dence is 1:5000 transfusions and the mortality is estimated to be between 5 and 10%.7-9 
Treatment is mostly supportive and in the majority of cases (80%) recovery is rapid and 
complete.7-9 Different etiologies for TRALI have been suggested, but most research has 
been focused on the role of donor leukocyte antibodies,7,10-12 as summarized in several 
recent reviews.13,14
Leukocyte antibodies are induced by previous exposure to allo-antigens. Such allo-
exposures occur either through pregnancies or through blood transfusions and organ or 
stem cell transplantation. As a consequence leukocyte antibodies are much more preva-
lent in female than in male donors.15-18 Since the UK first started to exclude plasma from 
female donors for transfusion in 2004, several other countries have also implemented or 
are considering to implement this policy to prevent TRALI.1,19,20 Although some encour-
aging data on the effects of such measures have been published,19,21 the evidence does 
not allow quantitative estimation of the effect of excluding plasma from female donors. 
Furthermore, the question arises whether for blood products that contain only small 
volumes of plasma, female donors also confer an increased risk of TRALI.22
To obtain a quantitative estimate of the contribution of blood products from female 
donors to the occurrence of TRALI is complicated because most TRALI patients have 
received transfusions from female as well as from male donors. However, some TRALI 
patients have received transfusions only from female or only from male donors, which 
we called Unisex cases. The ratio of female to male donors among these Unisex TRALI 
cases can be compared directly to the expected value calculated from the fraction of 
female donors in the respective total donor populations. We set out to quantify the 
association of female donors with the occurrence of TRALI by studying TRALI patients 
who had received transfusions either from female donors only or from male donors only.
design and meThods
design and study population
We performed a case-referent study consisting of TRALI patients who had been diag-
nosed clinically, without knowledge of serology or donor sex. Case-referent study is 
essentially synonymous to case-control study, but it is considered a more appropriate 
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name in some situations.23 In the current study the TRALI case-patients were compared 
to a reference value from the complete donor population, rather than to control-patients 
without TRALI, thus rendering the name case-referent study more appropriate.
Since TRALI is a rare complication and TRALI patients who have received transfusions 
only from female or only from male donors are inevitably even rarer, no single research 
group or country is likely to be able to collect enough of these cases to perform a mean-
ingful study. To overcome this problem we performed an international collaborative 
project.
We included only TRALI patients defined on clinical criteria alone, because TRALI that 
is defined by serological criteria (i.e. on the basis of presence of antibodies in donor 
blood), has the problem of circularity in reasoning since the diagnosis demands the 
presence of antibodies that are more frequent among female donors.24 We contacted 
groups who had previously published TRALI cases defined on clinical criteria alone, 
independent of serology or donor sex, and asked them to join the International TRALI 
Unisex Research Group.
measurements
TRALI cases
We asked each contributing group to identify all TRALI patients from their records. From 
all patients previously recorded as TRALI patients we further asked the collaborating 
groups to verify the sex of the donors of all products transfused within six hours before 
the onset of symptoms. Only those patients receiving all transfusions from donors 
of a single sex were eligible for inclusion in the present study. For these patients the 
presence of the other inclusion criteria for this study was checked retrospectively. The 
selection criteria were that the patient had presented with acute dyspnea (as a clinical 
sign of hypoxemia), within six hours after transfusion, without evidence of circulatory 
overload. For these patients, which we call “clinical TRALI” patients, we recorded the 
number of transfusions, the types of transfused products, and the sex of the involved 
donors. Furthermore, we collected data on all criteria of the definition of TRALI accord-
ing to the Canadian consensus conference; these criteria were acute dyspnea, within 
six hours after transfusion, without evidence of circulatory overload, in the presence 
of new or worsening bilateral lung infiltrates in chest X-rays, and the absence of other 
risk factors for acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).5,6 
Finally, specifications of blood products were recorded and all products containing 250 
mL or more of plasma (all plasma and platelet products) were classified as plasma rich, 
while all other products (red cells, always leukoreduced and always containing less than 
50 mL of plasma) were classified as plasma poor.
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Reference population
Each collaborating group also reported fractions of donations made by female donors as 
registered in their donation databases. For each TRALI patient we documented a unique 
fraction: the fraction of female donors of the specific blood product, in the country or 
region of the reporting group, at the date of occurrence of the TRALI.
Statistical analyses
Our analysis follows the line of reasoning of one of the methods that we have proposed 
earlier,25 which we briefly and informally recapitulate here. For each TRALI patient we 
first calculated that patient’s individual probability of receiving all transfusions from a 
female donor. This probability was equal to the individually matched fraction of dona-
tions made by female donors in the relevant donor population, raised to the power of 
the number of these products received by that patient. For example, a TRALI patient 
receiving three units of red cells from a donor population in which 40% of red cells are 
donated by female donors has a probability of receiving all three units from female 
donors of (0.40)3=0.064. For patients who received different product types the prob-
abilities were first calculated for the different product types separately and then those 
probabilities were multiplied. The probability of receiving all transfusions from male 
donors was calculated in the same way (in the example (0.60)3=0.216). Adding these two 
probabilities gives the probability of receiving all transfusions from donors of the same 
sex (in the example 0.064+0.216=0.28), which is the probability of being a Unisex case. 
We then calculated an expected fraction of Unisex cases caused by a female donor, by 
dividing each probability of receiving all transfusions from female donors by the prob-
ability of being a Unisex case (in the example 0.064/0.28=0.229).
The odds ratio and the corresponding 95% confidence interval (CI) were calculated 
with a matched analysis. The observed value for each individual case (i.e. 1 or 0, for all 
female or all male donors) was matched to the fraction of cases expected to be caused 
by female donors, as calculated for that individual case. In this matched analysis the size 
of the reference group, which was based on national registration data, was relatively so 
much larger than the number of cases (one per stratum) that the contribution of the 
reference group to the variance of the odds ratio was treated as negligible. The odds 
ratios are interpreted as relative risks (RR) throughout.
To estimate the population attributable risk (PAR) we calculated the average of the 
fractions of female donations from the different donor populations, by weighting for the 
number of TRALI patients contributed by each population. It can be shown25,26 that, for 
an average fraction p of female donors, the PAR equals:
PAR = pRR−p
pRR+(1−p)
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Where the RR is estimated by the OR from the matched analysis. The odds ratio and its 
variance (both from the matched analysis) were then used to calculate the population 
attributable risk and the corresponding 95% CI, according to standard formulas.26
Data were analyzed according to whether the transfused products were red cells or 
“plasma rich” (i.e. either plasma or platelets). Effect modification by product type was 
quantified by calculation of a ratio of relative risks (RRR) and corresponding 95% CI, ac-
cording to standard formulas.27
All analyses were repeated among the subgroup of patients of whom we had suf-
ficient information to assess whether the diagnosis was conform to the Canadian 
consensus criteria5,6: patients who had bilateral infiltrates proven in chest X-rays and 
who had no other risk factors for ALI/ARDS (i.e. excluding “possible TRALI”). In this way 
we could compare the results in all clinical TRALI patients with those patients that had 
TRALI according to the Canadian consensus definition.
resulTs
Population characteristics
Based on a previous literature study,24 we identified 43 different research groups from 52 
publications, describing clinically defined TRALI patients. All groups for whom email ad-
dresses could be retrieved were contacted. Apart from the Netherlands, six more groups 
had the relevant data available and were interested in collaborating on this study. Col-
lected data pertained to cases occurring between June 1991 and October 2007.
A total of 83 clinical TRALI patients were included, all presenting with acute dyspnea, 
without evidence of circulatory overload, within six hours after a transfusion. Of these 
patients 67 (81%) had received only red cells, 13 (16%) had received only plasma rich 
products (7 plasma, 6 platelets) and 3 (3.6%) had received both red cells and plasma rich 
products. On average the TRALI patients had received 1.8 transfusions (range 1-8) in the 
six hours preceding the onset of symptoms.
Of 67 cases caused by a transfusion of red cells 23 had another risk factor for acute 
lung injury, and in 17 no chest X-rays were available (3 patients had both). Therefore, 
of the cases caused by a transfusion of red cells a total of 30 (45%) were classified as 
TRALI patients according to all criteria of the Canadian consensus definition. Of 13 cases 
caused by transfusion of a plasma rich product 2 had another risk factor for acute lung 
injury, while in 1 (8%) a chest X-rays was not available, and the remaining 10 (77%) were 
classified as TRALI patients according to all criteria of the Canadian consensus definition.
The distribution of patients, according to product type and geographical location, 
with numbers of cases associated with male and female donors and corresponding 
percentage of female donors in the reference group are given in Table 1. For both red 
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cells and plasma the fraction of products donated by female donors ranged from 0.22 
in Poland to 0.51 in Finland, while for platelets it ranged from 0.02 in Poland to 0.50 in 
Spain (Table 1).
female donors and Trali risk
Among 67 red cell recipients the relative risk (RR) of clinical TRALI after a transfusion from 
a female donor was 1.2 (95% CI 0.69 to 2.1) in the matched analysis; among 13 recipients 
of plasma rich products (plasma or platelets) the RR was 19 (1.9 to 191) (Table 2). After 
restricting the analyses to cases who had proven bilateral infiltrates in chest X-rays and 
no other risk factors for ALI/ARDS (i.e. Canadian consensus definition), the RR for 30 red 
cell recipients remained similar at 0.86 (95% CI 0.37 to 2.02) while the RR for 10 recipients 
of plasma rich products increased to 66 (1.3 to 3465) (Table 2).
Table 1. Distribution of patients according to product type, donor sex, and geographical location
red cells Plasma Platelets
TRALI 
patients
(♀/♂ donors)
Reference group
(percentage ♀ 
donors)
TRALI 
patients
(♀/♂ donors)
Reference group
(percentage ♀ 
donors)
TRALI 
patients
(♀/♂ donors)
Reference group
(percentage ♀ 
donors)
denver, co, usa 5/3 45% N.A. N.A. N.A. N.A.
netherlands 5/16 41% -/2 10% -/1 41%
Poland 1/19* 22% -/1* 22% -/2 2%
rochester, mn, usa 6/5* 43% 3/1* 47% 2/- 47%
spain 4/3 50% N.A. N.A. 1/- 50%
finland 2/- 51% 1/- 51% N.A. N.A.
united kingdom 1/-* 50% 2/-* 50% N.A. N.A.
Values are numbers of patients and percentage of donations from female donors in the corresponding 
reference group.
Where changes in fractions donated by female donors occurred over time the represented fractions are 
weighted averages, weighted for the number of TRALI patients in each period.
N.A.: Not applicable (i.e. no Unisex TRALI cases associated with this product type in this country or region, 
n=0)
* Patients receiving both plasma and red cells were counted in both categories (only in this table). This oc-
curred three times, once in Poland, once in Rochester and once in the UK.
Table 2. Relative risk for developing TRALI after a transfusion from a female donor
all cases canadian consensus*
red cells 1.2 (0.69 to 2.1) 0.86 (0.37to 2.0)
Plasma rich 19 (1.9 to 191) 66 (1.3 to 3465)
Values are relative risk and (between parentheses) 95% confidence intervals.
* Only those cases defined completely according to the definition of the Canadian consensus conference.5,6
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The ratio of the relative risks of red cell and plasma rich product recipients was 16 (1.5 
to 170), the p-value for the difference in relative risks between these groups was 0.023. 
After limiting to the Canadian consensus definition the ratio became 77 (1.3 to 4410) 
and the p-value for a difference between the groups became 0.046.
The percentage of cases preventable by the exclusion of female donors (population 
attributable risk, PAR) was 7.0% (-17% to 26%) among red cell recipients, and 86% (17 to 
98%) among recipients of plasma rich products (Table 3).
discussion
The risk of TRALI was increased among recipients of plasma rich products from female 
donors, but not among recipients of red cells from female donors. A strong association 
of female donors with the risk of TRALI was expected because, according to the litera-
ture, most TRALI cases are caused by donor leukocyte antibodies 24 and the prevalence 
of these antibodies in female donors is several times higher than in male donors.15-18
A unique feature of this study was the restriction to Unisex TRALI cases: patients 
who had received transfusions either only from male or only from female donors. Most 
patients who develop TRALI have received transfusions from several donors of either 
sex, and the one donor causing the TRALI can not be directly identified; therefore the 
sex of the causal donor remains unknown. In our study, since only patients with donors 
of a single sex were included, the sex of the causal donor was known even if the causal 
donor was not identified. Our approach solves the problem of attenuation caused by 
transfusions from multiple donors.25
Due to the international collaborative effort of this study TRALI patients were selected 
from several different centers or countries with different sized background populations. 
It is therefore not possible to compare the selected patients with the unselected part of 
the total population of TRALI patients, since there is no single identifiable background 
population. However, since all TRALI patients were originally diagnosed independently 
of donor sex and serology this can not have biased our results with respect to donor 
sex as a risk factor for TRALI. The separate effect estimates for red cells and plasma rich 
Table 3. Percentage of TRALI cases preventable by the exclusion of female donors
all cases canadian consensus*
red cells 7.0 (-17 to 26) -5.9 (-45 to 23)
Plasma rich 86 (17 to 98) 96 (-126 to 100)
Values are percentages of population attributable risk (PAR) and (between parentheses) 95% confidence 
intervals.
Negative PAR values can only be interpreted as indicative of some protective effect, but not of any size of 
that effect.
* Only those cases defined completely according to the definition of the Canadian consensus conference.5,6
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products are therefore valid in any population, but remain specific for those products. To 
apply them to a different population all that is needed is to know the relative contribu-
tion of the different product types in that population.
The main limitation of this study, pertaining only to the results for plasma rich prod-
ucts, is the limited number of cases caused by these products. The selection of Unisex 
cases causes an indirect selection of cases with few transfusions, who in turn will have 
rarely received only transfusions of plasma rich products. Although the distribution of 
product types among the patients in our study may well be different from the back-
ground population, no bias will be introduced by the selection. Firstly, since we analyzed 
red cells and plasma rich products separately, the fraction of TRALI cases caused by each 
product type in the background population is irrelevant. Secondly, the lesser number of 
transfusions received by TRALI patients in our study, in comparison to other published 
series, should not cause bias either. The mechanism by which TRALI is caused is consid-
ered to be an immunologic reaction to a single transfusion25 - which is independent of 
the number and type of the other transfusions received by the patient. In spite of the 
small number of cases caused by plasma rich products, a strong association of plasma 
rich products from female donors with an increased risk of TRALI was observed, while no 
such association was observed for red cells.
The most surprising finding was this lack of association of female donors and the risk 
of developing a TRALI in red cell recipients. To appreciate this finding we considered an 
alternative explanation: if not all included cases were really TRALI patients the effect 
of donor sex would be diluted, obscuring a true association. One source of such mis-
diagnosis could be the patients of whom we did not have all information to be certain 
that the diagnosis was conform to the Canadian Consensus conference. However, the 
exclusion of these patients did not support the notion that the effect was diluted by 
their inclusion among the clinical TRALI patients. In this analysis increasingly stringent 
selection criteria reduce the number of potentially misclassified patients. Misclassified 
patients would contribute donors to the analyses who did not actually cause a TRALI 
case. These donors would therefore follow the sex distribution of the reference group, 
thus causing the TRALI group to become more similar to the reference group. Excluding 
those patients would therefore increase the difference between the TRALI group and the 
reference group. However, no such increase was observed in red cell recipients who, if 
anything, showed an inverse association with female donors after exclusion of clinical 
TRALI patients who did not fulfill all criteria of the consensus definition. Therefore, mis-
classification of TRALI patients does not seem a likely explanation for the lack of associa-
tion between donor sex and the risk of TRALI in red cell recipients. Only for recipients of 
plasma rich products did restriction to consensus definition cases cause an increase in 
relative risk – which indicates that the association might even be stronger.
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Another possible source of misclassification could be transfusion associated circula-
tory overload (TACO). In accordance with the Canadian consensus definition the exclu-
sion of TACO was based on the criterion of “no evidence of circulatory overload”, which 
does not specify the type of evidence of which the presence should be excluded. The 
absence of circulatory overload is therefore mainly based on clinical judgment, which 
makes this criterion the most subjective in the definition. However, to explain our find-
ings in red cell recipients almost complete misclassification of these patients would be 
necessary. Even with the subjective nature of this clinical judgment, it seems unlikely 
that nearly all observed TRALI patients related to red cells would be misclassified TACO. 
This is especially unlikely since a strong association with donor sex was observed in 
recipients of plasma rich products, indicating those patients were not misclassified. 
Furthermore, Unisex cases have on average received only few transfusions, which also 
reduces the risk of TACO.
To compare our findings with what was known from the literature, we performed a 
systematic review of the literature to summarize the direct evidence of the relation be-
tween female donors and TRALI- see Appendix for methodology and selection criteria. 
We found 6 such studies: 4 with a contemporary control group and 2 with a before/after 
comparison (Table 4).
None of these 6 publications investigated the difference between plasma rich and 
plasma poor products. Publications that make before/after comparisons (i.e. before 
and after introduction of a male-only plasma measure) run the risk of clinical suspicion 
or reporting bias. Only a small portion of TRALI patients are reported, either through 
lack of clinical suspicion/recognition or through poor reporting. The fraction of TRALI 
patients that is reported is inconsistent and highly variable over time and is likely to 
change strongly after well publicized and dramatic measures for the prevention of TRALI 
(i.e. the exclusion of female donors). Therefore, a difference in the number of reported 
Table 4. Six publications investigating the relation between female donors and TRALI
Publication Quantitative interpretation
limited by:
description
gajic 2007 36 Difference in number of 
transfusions
Amount of female plasma compared between TRALI 
patients and controls
sanchez 2007 37 Statistical power Only six cases (pilot study)
imoto 2007 38 Statistical power Only three cases
wright 2008 19 Before/after comparison Number of reported cases before vs. after male-only 
plasma measure
chapman 2009 21 Before/after comparison Number of reported cases before vs. after male-only 
plasma measure
nakazawa 2009 39 Difference in number of 
transfusions
Risk of TRALI compared between male-only and mixed 
plasma recipients
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TRALI patients before and after implementation of this preventive measure does not 
necessarily correspond to a real difference in the number of TRALI patients.
Of the 4 publications with a contemporary control group 1 only included six cases and 
1 included only three cases. The remaining 2 did not correct for a difference in the num-
ber of transfusions (Table 4). TRALI patients have on average received more transfusions 
than other patients which are used as control patients in these studies. Both the chance 
of receiving male-only plasma and the amount of female plasma received depend on 
the total number of transfusions. A higher number of transfusions is strongly related to 
a higher risk of TRALI. Without correction this precludes quantitative conclusions from 
an observed difference in either the prevalence of TRALI between male-only and mixed 
plasma recipients, or a difference in the amount of female plasma received between 
TRALI patients and control patients.24,25
Considering the limitations of previous studies, their quantitative conclusions are 
uncertain. The methodology which we advocate here and elsewhere,25 is aimed at over-
coming these potential shortcomings. Furthermore, our study makes a clear distinction 
in the analyses between plasma rich products and red cells and shows a striking differ-
ence between the associations of female donors with TRALI caused by these products.
Several countries have implemented policies excluding female donors from the dona-
tion of plasma, to prevent TRALI.1,19,20 Our findings suggest that the vast majority of the 
TRALI cases caused by plasma rich products are indeed preventable by the exclusion of 
female donors. However, to estimate the overall effect on the occurrence of TRALI we 
also need to estimate the relative contribution of plasma rich products to the occur-
rence of TRALI, which can not be estimated directly from our data. The literature gives 
estimates of the contribution of red cells to the occurrence of TRALI varying from one 
third to more than 90%.28-32 Based on the literature and our own previously published 
experience29 we assume that on average approximately half of all TRALI cases are caused 
by transfusion of red cells alone. Therefore, exclusion of female donors from donation of 
plasma rich products might prevent roughly half of all TRALI cases.
In TRALI caused by red cell transfusions our data indicate the role of female donors to 
be negligible. This suggests that current red cell preparation procedures, by reducing 
the amount of plasma in the product, already suffice to effectively reduce the risk posed 
by donor leukocyte antibodies in these products. Therefore, removing the small amount 
of remaining leukocyte antibodies from red cells is likely to have only limited effect. This 
is in agreement with current thinking about the pathogenesis, which suggests that red 
cells may cause TRALI by different mechanisms.30,33-35
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aPPendix: sysTemaTic review of The liTeraTure
To compare our results with what was known in the literature, we performed a systematic 
review. On December 24 2009 we searched the PubMed database for all publication on 
TRALI and donor sex using the search strategy: (“transfusion related acute lung injury”[All 
Fields] OR TRALI[All Fields]) AND ((“female”[MeSH Terms] OR “female”[All Fields]) OR 
(“sex”[All Fields] OR “sex”[MeSH Terms]) OR (“male”[MeSH Terms] OR “male”[All Fields]) 
OR “gender”[All Fields]) AND (“donor”[All Fields] OR “donors”[All fields]).
We retrieved 125 publications, 100 contained original data, of which 86 had TRALI as 
their primary focus. Of these 86, only 22 actually investigated donor sex as a risk factor, 
while most only mentioned donor sex in relation to antibody testing in a case report or 
case series. Only 4 of the 22 remaining publications included a contemporary control 
group and two made a before/after comparison (Table 4). This left only six publications 
that actually made the comparison we were interested in. The evidence available, from 
the selected publications, for a relation between female donors and TRALI risk was sum-
marized (Table 4).
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absTracT
background
Donor white blood cell (WBC) antibodies are thought to increase the risk of transfusion-
related acute lung injury (TRALI). WBC antibodies can be present in blood products from 
donors who have been allo exposed. Alloexposed donors are increasingly excluded 
from donating plasma, but can still donate plasma-poor products. We aimed to quantify 
the contribution of alloexposed donors to the occurrence of TRALI for different blood 
product types.
study design and methods
We performed a case-referent study including all reported TRALI patients and all Dutch 
blood donors. Data on alloexposure status of donors of all TRALI cases reported between 
January 2004 and October 2008, in the Netherlands, were compared to information on 
the total donor population.
results
Alloexposure status of all 223 involved donors was compared to the expected status. 
The overall percentage of TRALI cases that could have been prevented by the deferral of 
all alloexposed donors (i.e. population-attributable risk [PAR]) was 51% (95% confidence 
interval [CI], 14% to 88%). In 19 recipients of exclusively plasma-poor products (mostly 
red cells [RBCs]), alloexposure of the donors was not associated with TRALI, while in 28 
recipients of both plasma-poor and plasma-rich products (>200 mL plasma), the PAR 
was 94% (95% CI, 34% to 100%).
conclusions
Alloexposed donors conferred an increased risk of TRALI in recipients of plasma-rich 
products, but not in recipients of plasma-poor products. Although WBC antibodies are 
an important risk factor for TRALI, amongst RBC recipients another risk factor must be 
more important.
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inTroducTion
Transfusion-related acute lung injury (TRALI) is a clinical syndrome of respiratory dis-
tress that develops within 6 hours of transfusion of one or more blood products.1,2 With 
an estimated incidence of 1:5000 transfusions, TRALI is one of the most common serious 
side effects of blood transfusions.3 As a form of acute respiratory distress syndrome it 
has a relatively mild prognosis with a mortality commonly estimated to be between 5 
and 10%, and the majority of patients spontaneously recover within 96 hours, without 
long term sequelae.3-5 However, due to the widespread use of blood transfusions, total 
morbidity and mortality associated with TRALI poses a considerable problem.6-8
Since the publication of the first large case series,3 it has been suggested that TRALI 
can be caused by antibodies directed against either human neutrophil antigens (HNA) 
or human leukocyte antigens (HLA) of both class I and class II.3,9-13 These white blood 
cell (WBC) antibodies arise from exposure of the immune system to allogeneic cells and 
tissues (alloexposure).14,15 This alloexposure can occur through pregnancy, transfusion 
of blood or blood components, and transplantation of stem cells, tissues, or organs.
As a consequence parous donors and donors who have received blood transfusions 
are more likely to possess WBC antibodies.14-19 The prevalence of these antibodies in-
creases from below 5% in subjects without known alloexposure to 10-15% after blood 
transfusions or a single pregnancy to well over 30% after three or more pregnancies.14-19 
Alloexposed donors are therefore considered to be at increased risk of causing TRALI 
in recipients of their blood.20,21 These donors are thought to confer this increased risk 
primarily through the plasma-rich products made from their blood, since these contain 
the highest quantities of antibodies. Therefore, plasma from female donors is now ex-
cluded from use for transfusion in an increasing number of blood services.6,22-25 In some 
instances these measures also include other products considered to be plasma-rich 
(some types of platelet [PLT] products) and sometimes also male donors with a history 
of blood transfusion.6,24
However, the evidence remains largely circumstantial and a quantitative estima-
tion of the expected benefit of these measures is therefore not possible. This was also 
confirmed in a recent review of the literature on the contribution of female donors to 
the occurrence of TRALI, which was published in conjunction with an international col-
laborative case-referent study on the same subject.26 In the absence of such quantifica-
tion, these measures are based on the precautionary principle. The main obstacle to the 
quantification of the preventable number of TRALI cases is methodological complexity. 
Most patients have received transfusions from more than one donor before developing 
TRALI. Both ignoring this problem and applying conventional methods to correct for the 
number of transfusions result in severely biased effect estimates.27 Therefore, previous 
estimates of the role of donor-related risk factors, such as donor sex, parity, transfu-
Danielle binnenwerk - CP 4.indd   57 30-07-15   12:31
58 Chapter 4
sion history, and presence of WBC antibodies cannot be used to predict the expected 
benefits of measures directed at removing these risk factors from the blood supply.
Furthermore, the question has now arisen how much WBC antibody containing plasma 
is necessary to cause TRALI.28 If the small amount of plasma present in red blood cells 
(RBCs) is sufficient, this could have the obvious implication of excluding alloexposed 
donors from all forms of blood donation. On this subject, only anecdotal evidence ex-
ist to date and further investigation of differences between product types is therefore 
necessary.28
We applied new statistical methods, which have been shown to adequately correct 
for the number of transfusions received,27 to quantify the contribution of alloexposed 
donors to the occurrence of TRALI caused by plasma-poor and plasma-rich products, in 
all reported TRALI cases between January 2004 and October 2008 in the Netherlands.
meThods
study design
Ethical approval was granted by the medical ethical committees of the Leiden University 
Medical Center and the Sanquin Blood Bank. We performed a case-referent study for 
which we used the prospectively collected data on all TRALI patients reported in the 
Netherlands from January 2004 to October 2008. For each included TRALI patient do-
nors of transfused blood components were identified and their alloexposure status was 
determined (see appendix for details). Donors were considered alloexposed if the donor 
had received one or more blood transfusions, if the donor had been pregnant at least 
one time (including terminated pregnancies), or both.
Alloexposure status of donors associated with TRALI patients was compared to the al-
loexposure status of a reference group of donors (see appendix for details). These control 
donors donated blood for products that represent the source population of the blood 
components from which the components transfused to TRALI patients were randomly 
drawn. The alloexposure status of the donors of each TRALI patient was matched to the 
alloexposure status that would have been expected, based on the alloexposure status of 
the reference group (as described below).
Trali patients: definition, reporting, and verification
TRALI was defined, according to the Canadian consensus definition, as acute respira-
tory distress with new or worsening bilateral infiltrates in the chest radiograph in the 
absence of evidence of circulatory overload, within 6 hours after completion of a blood 
transfusion.1,2 In accordance with the consensus definition, a distinction was also made 
between TRALI and “possible TRALI”, the latter being clinically diagnosed TRALI in the 
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presence of other risk factors for acute lung injury.1,2 All further mention of TRALI will 
refer to the complete group of all TRALI patients, including possible TRALI. When pos-
sible TRALI is excluded, this is stated explicitly.
Suspected TRALI cases were reported to Sanquin (the national blood supply orga-
nization in the Netherlands) and TRIP (Transfusion Reactions In Patients, the national 
hemovigilance office in the Netherlands). Reports from hospitals are made by either the 
hospital’s hemovigilance staff or the responsible physicians.
Reports to Sanquin were verified by physicians of Sanquin’s clinical consultation 
service and reports to TRIP were independently verified by TRIP physicians. Physicians 
from both organizations received additional clinical information from the reporting 
hospitals, as required for verification of the TRALI case. All cases were verified on clinical 
criteria alone, without any knowledge on the donor’s sex or alloexposure status. Records 
of Sanquin were then compared to those of TRIP for further verification. All confirmed 
TRALI patients were further classified as TRALI without other risk factors for acute lung 
injury or possible TRALI.
blood products
Transfused blood products were classified as either plasma-poor or plasma-rich. PLT 
concentrates derived from multiple donors were treated as multiple products in all 
analyses.
Plasma-poor products were defined as all products containing less than 40 mL 
plasma. This included RBCs, the PLTs from donors supplying only PLTs (i.e. not plasma) 
for a pooled PLT product (i.e. including four of every five donors for PLTs in plasma and 
all donors for PLTs in PLT additive solution-II [PAS II]).
Plasma-rich products were defined as all products containing more than 200 mL 
plasma. This included fresh-frozen plasma (FFP) and the PLTs (and plasma) from the do-
nor supplying both PLTs and plasma for pooled PLTs in plasma. Although apheresis PLTs 
are a standard product for some indications in The Netherlands, their use is relatively 
rare and no TRALI cases occurring after the transfusion of apheresis PLTs were therefore 
included in any analyses.
Plasma measure
Since October 1, 2006, all plasma donated for transfusion in the Netherlands is from 
never transfused male donors. In September 2007 the first TRALI patient receiving 
plasma donated after October 1, 2006, was reported. Therefore, all TRALI cases oc-
curring since September 2007 are considered “postplasma measure”. For the primary 
analyses only TRALI cases occurring before September 2007 are included, since after the 
plasma measure it was not possible for plasma to be donated by an alloexposed donor. 
However, the subgroup of patients receiving only plasma-poor products could not have 
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been affected by the plasma measure. Therefore, an additional analysis was performed 
including all TRALI patients receiving only plasma-poor products from January 2004 to 
October 2008.
statistical analyses
We aimed to estimate the contribution of alloexposed donors to the occurrence of TRALI. 
This contribution was expressed as a population-attributable risk (PAR; the fraction of 
TRALI cases that could have been prevented by the exclusion of all alloexposed donors).
As previously described, standard statistical correction methods are inadequate to 
correct for the number of transfusions received by each TRALI patient.27 We therefore 
used an adapted form of standardization that has been shown in simulation studies to 
give a valid estimate of the contribution of donor-related risk factors to the occurrence 
of TRALI.27
Briefly, the difference of the observed number of alloexposed donors of each TRALI 
patient from the expected number for that same TRALI patient was calculated. These dif-
ferences were used to estimate the number of TRALI patients in whom the causal trans-
fusion was provided by an alloexposed donor. The difference of this number from the 
number of TRALI patients expected to be caused by alloexposed donors was considered 
the excess number of TRALI patients caused by alloexposure of donors. The maximum 
excess number was the total number of TRALI patients minus the number expected to 
be caused by alloexposed donors. Dividing the excess number by the maximum excess 
number gives the PAR (the fraction of TRALI cases that could have been prevented by 
the exclusion of all alloexposed donors).
We first performed these analyses for all TRALI patients, giving an estimate of the 
effect of exclusion of all alloexposed donors from donations of any type. The analyses 
were repeated, selecting patients who had received only plasma-poor product, only 
plasma-rich products, or mixed product types (both plasma-poor and plasma-rich prod-
ucts). Finally, separate analyses were performed for all groups by repeating all analyses 
after exclusion of the possible TRALI cases.
resulTs
Trali patients
From January 2004 to September 2007 a total of 50 TRALI cases were reported in the 
Netherlands. Of these, 11 also had other risk factors for acute lung injury and were 
therefore classified as possible TRALI. Table 1 shows the numbers of donors and different 
product types involved separately for all 50 TRALI cases - 39 TRALI cases excluding all 
possible TRALI and in 11 possible TRALI.
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From September 2007 to October 2008, an additional 21 TRALI cases were reported, of 
which 11 (including four possible TRALI) received only plasma-poor products. These 11 
patients were included in the additional analysis presented in table 2. All other analyses 
are restricted to the 50 TRALI patients reported before the plasma measure became ef-
fective. Of 288 donors involved in the total of 61 included TRALI cases data on pregnancy 
and transfusion history could be gathered for 283 (98.3%).
Table 1: Numbers of TRALI patients, transfusions, and involved donors, according to product types and 
classification as TRALI and “possible TRALI”.
TRALI Possible TRALI Total
Number of cases 39 11 50*
Number of transfusions 179 (4.6/case) 32 (2.9/case) 211
Number of donors 223 (5.7/case) 44 (4.0/case) 267
Red cells 110 (49%) 23 (52%) 133
Platelets† 55 (25%) 15 (34%) 70
FFP 58 (26%) 6 (14%) 64
* Table 1 represents only TRALI cases occurring prior to September 2007, showing a representative compo-
sition of the population of TRALI patients before the plasma measure became effective.
† Platelets are mostly pooled concentrates of buffy coat derived platelets from five donors in the plasma 
of one of those donors. Three TRALI cases were reported after receiving pooled concentrates of buffy coat 
derived platelets from five donors in PAS II. The reported 70 platelet donors represent 14 platelet transfu-
sions: 11 for 10 TRALI cases and 3 for 2 “possible TRALI” cases.
Table 2: PAR of alloexposed donors, according to product types*
Number in analyses
Patients† Donors PAR (%) 95% CI
Overall‡ 50 267 51%  (14% to 88%)
Plasma-poor‡ Before measure§ 19 38 -10%  (-52% to 31%)
Total§ 30 59 -3.5%  (-36% to 29%)
Plasma-rich‡ 3 6 24%  (56% to 100%)
Mixed‡ 28 223 94%  (34% to 100%)
* A negative PAR value can only be interpreted as indicative of some protective effect, but not of any size 
of that effect
† Includes all patients until September 2007, except for the third row where, as indicated, patients were 
included until October 2008.
‡ Overall: all reported TRALI patients. Plasma-poor: patients receiving only products containing less than 40 
mL plasma per donor. Plasma-rich: patients receiving only products containing more than 200 mL plasma 
per donor. Mixed: patients receiving both plasma-rich and plasma-poor products.
§ Before measure: only patients before the plasma measure became effective (September 2007); these are 
from the same period as the other groups (i.e., overall, plasma-rich, and mixed). Total: also including 11 
patients, receiving plasma-poor products only, who were reported between September 2007 and October 
2008.
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alloexposure in reference subjects
A final number of 1040 donors with known alloexposure status was used to determine 
the expected alloexposure status of donors involved in TRALI cases. This included 528 
female donors and 512 male donors. Pregnancy was reported by 352 donors and a his-
tory of blood transfusion by 24. Of these donors 13 reported both previous pregnancies 
and blood transfusions. Of the resulting total of 363 alloexposed donors 354 (98%) were 
female. Alloexposed donors constituted 68% of all female donors.
The mean number of donations in 2007 was 2.67 for male donors and 1.84 for female 
donors. Alloexposure status was not associated with the number of donations. It was 
1.86 for non alloexposed female donors and 1.84 for alloexposed female donors.
alloexposed donors and Trali risk
The expected percentage of alloexposed donors among 267 donors involved in 50 
TRALI cases was 27% (standardized for products types donated and year of donation); 
the observed percentage was 66%. After exclusion of all possible TRALI among the 
remaining 223 donors, involved in 39 cases, the expected percentage was 27% and the 
observed was 65%.
Table 2 represents the percentage of cases preventable by the deferral of alloexposed 
donors (PAR). The overall PAR of receiving a transfusion from an alloexposed donor was 
51% (95% confidence interval [CI], 14% to 88%). There were only three patients who had 
received exclusively plasma-rich products. For patients who had received both plasma-
rich and plasma-poor products the PAR of receiving a transfusion from an alloexposed 
donor was 94% (34% to 100%; Table 2). In 19 patients who had received only plasma-
poor products (mostly RBCs) allo-exposure of the donors was not associated with TRALI.
exclusion of possible Trali cases
The findings were similar after exclusion of possible TRALI cases (Fig. 1): The PAR for the 
total group was 60% (17% to 100%). For plasma-poor product recipients the PAR was 
-28% (-86% to 30%). For recipients of both plasma-rich and plasma-poor products the 
PAR was 100% (44% to 100%).
discussion
Among recipients of only plasma-poor blood products alloexposure of donors was not 
associated with an increased risk of TRALI. However, among recipients of both plasma-
rich and plasma-poor blood products alloexposure of the donors was a major risk factor 
for TRALI. This suggests first that alloexposure of the donor is an important risk factor for 
TRALI when plasma-rich components are transfused and second that the plasma-rich 
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products are more likely to have caused the TRALI in recipients of both plasma-rich and 
plasma-poor products.
We used alloexposure of the donors as a marker for the increased prevalence of WBC 
antibodies. Although only a minority of alloexposed donors actually develops WBC 
antibodies, nearly all WBC antibodies are found in alloexposed donors. We assumed that 
there is no other reason, besides WBC antibodies, why alloexposed donors can increase 
the risk of TRALI. It can then be shown that the percentage of TRALI cases preventable 
by the exclusion of alloexposed donors equals the percentage preventable by the exclu-
sion of all donors with WBC antibodies. This can be understood since, first, exclusion of 
alloexposed donors also excludes donors with WBC antibodies and therefore prevents 
the cases caused by those antibodies. Second, we do not expect it to prevent any other 
cases than those caused by WBC antibodies since alloexposed donors are not known 
to cause TRALI through any other mechanisms (i.e., other alloexposure-related, but 
antibody-independent mechanisms). This is one of the major advantages of using the 
PAR as the effect estimate, since it removes the need to actually determine the presence 
or specificity of WBC antibodies.
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figure 1: Population attributable risk of allo-exposed donors for all 50 Trali patients and for 39 
Trali patients, excluding all possible Trali. (●) The PAR for all 50 TRALI patients; (■) the PAR for 39 TRALI 
patients after excluding all cases of possible TRALI. “Overall” indicates the estimate for all patients, regard-
less of product mix. “Plasma-poor” indicates the estimate for patients receiving only plasma-poor products 
(<40 mL plasma per donor). “Mixed” indicates the estimate for patients receiving both plasma-poor and 
plasma-rich products (i.e., excluding patients receiving either only plasma-poor or only plasma-rich, as op-
posed to “Overall”, which includes both these groups and “Mixed”). Bars represent 95% Cis. The dashed line 
indicates the level of null-effect. A negative PAR value can only be interpreted as indicative of some protec-
tive effect, but not of any size of that effect.
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Beyond the distinction between TRALI and possible TRALI, we ignored all other data 
on potential patient risk factors. All diseases can be considered multicausal and TRALI 
is no exception in this respect.29 However, this was a study of donor-related risk factors. 
We consider these risk factors more interesting, since they are relatively easy to control, 
while the patient’s predisposition for developing TRALI is usually not readily influenced.
An assumption necessary for the used analyses to be valid is that the calculated prob-
ability of receiving a transfusion from an alloexposed donor should really represent this 
probability at the moment of issuing of the product transfused to the TRALI patient. For 
this to be true the reference group has to be representative of a nonselected, random 
sample of all actively donating donors. We have no reason to assume that in the few 
years of our study the average alloexposure status of the Dutch female or male changed 
substantially. Furthermore, we corrected for any changes in female-to-male ratio among 
donations.
Although we report one of the largest known case series of TRALI patients, a major 
limitation of our study was still the size. The limited size precluded analyses by product 
type and forced us to lump several product types together into plasma-rich and plasma-
poor products. Even so, we still did not find enough recipients of only plasma-rich 
products (i.e., only three patients) to report an effect estimate for this group. Obviously 
patients receiving only plasma-rich products are rare and so is TRALI. The combination 
is therefore even rarer and difficult to study. However, since plasma-poor products show 
no association with alloexposed donors, any association seen in the patients receiving 
both must be due to plasma-rich products. Since the PAR in this group is close to one, it 
is suggested that nearly all the cases in this group are caused by plasma-rich products. 
Further, the PAR for these plasma-rich products must also be close to one. This is further 
supported by the differences between the recipients of plasma-poor products and the 
total group (the latter reflecting the weighted average of all plasma-rich products and 
all plasma-poor products).
TRALI is known to be underreported and this underreporting may be selective for 
plasma-rich or plasma-poor products. This could influence our conclusion that plasma-
rich products are more likely to cause TRALI, but none of our other conclusions. Only if 
reporting was selective for the presence of WBC antibodies or alloexposed donors, this 
could cause bias in the conclusions that TRALI after plasma-poor products is not associ-
ated with alloexposed donors and that TRALI after plasma-rich products is. However, 
since this information was not available to the reporting physicians, this reporting bias 
cannot be a problem in our study.
Our results indicate that half of all TRALI cases may be preventable by the exclusion of 
all alloexposed donors, which is in close agreement with a previous estimate of the PAR 
of female donors.26 Furthermore, our findings confirm that alloexposure of the donor is 
the dominant determinant for TRALI in patients receiving plasma-rich products, while 
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for plasma-poor products other risk factors must be more important. This is in agree-
ment with the characteristics of a limited number of TRALI cases reported in the 2008 
annual Serious Hazards Of Transfusion (SHOT) report.25 Of 17 TRALI cases described in 
this report, 11 involved the transfusion of RBCs (six received only RBCs). In none of the 
ten completely investigated cases were concordant WBC antibodies found in donors 
of the transfused RBCs. For all five cases in which WBC antibodies were identified, the 
implicated products were either fresh frozen plasma (three cases) or PLTs (two cases).25 
In this study we did not observe a sharp decrease in the total annual number of reported 
TRALI cases after the plasma measure. However, as previously described by Wiersum-
Osselton and colleagues30 during the same period in The Netherlands we did see the 
previous trend of strong increase level off. Simultaneously a shift was observed from 
plasma-rich towards plasma poor-products.30
We also repeated all analyses after exclusion of all possible TRALI cases. Some of these 
possible TRALI cases were probably not TRALI, but rather acute lung injury caused inde-
pendently of transfusion. Therefore, they should not show any association with risk fac-
tors for TRALI and cause some dilution of the estimated effect. Consequently, excluding 
these cases can be expected to increase any observed association. Only minor increases 
were observed. The estimate for the total group (overall estimate) reflects a weighted 
mean of effects exerted through plasma-poor and plasma-rich products. Changes 
therefore reflect the weighted mean of changes in different directions (i.e., simultaneous 
increase of a negative association for plasma-poor products and a positive association 
for plasma-rich products) and can not be interpreted directly.
In conclusion, our findings confirm the increased risk of TRALI associated with alloex-
posed donors, which are used as a proxy for WBC antibodies. However, this association 
was only observed for plasma-rich products. Alloexposed donors are almost exclusively 
female and female donors are increasingly being excluded from donation of plasma-rich 
products. As shown recently, deferral of all donors reporting a history of alloexposure 
would effectively decrease the prevalence of WBC antibodies among donors to a similar 
extend as excluding all female and transfused male donors.31 In the Dutch situation this 
would cause a total deferral of 25% of all donors.31 Irrespective of the exact deferral 
strategy chosen, most blood banks in developed countries now have a deferral strat-
egy aimed at the exclusion of WBC antibodies in place. Therefore, the contribution of 
plasma-rich products from alloexposed donors to the occurrence of TRALI is dwindling 
and the relative importance of RBC transfusions is steadily growing.
Already nearly half of the reported TRALI cases in this study were caused by RBCs alone. 
At present little is known about risk factors for TRALI related to RBCs. With the growing 
contribution of RBCs to the occurrence of TRALI these risk factors need to be identified. 
In this context biological response modifiers seem the most likely candidate.13,32,33 Most 
of these small-molecule, inflammatory mediators are known to accumulate in cellular 
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blood products during storage.13,33 However, a clear association of TRALI with storage 
time has not yet been demonstrated.
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aPPendix
donors of Trali patients: identification, alloexposure verification
For each included TRALI patient all blood components transfused within six hours be-
fore the onset of symptoms were identified by a physician of the reporting hospital. All 
donors of these components were then identified in the database of the national blood 
supply organization in the Netherlands.
Since alloexposure variables like parity and transfusion history are not routinely 
collected, we contacted all donors to obtain this information. Donors were sent a ques-
tionnaire by post, if necessary they received a reminder (with the same questionnaire 
included), and if they did not return the questionnaire they were also contacted by 
telephone. The questionnaire included questions on the donor’s history of transfusions 
and pregnancies. Donors were considered alloexposed if they reported either one or 
more pregnancies, one or more blood transfusions, or both.
For donors for whom the alloexposure status could not be ascertained the average 
allo-exposure status from the other donors of the same TRALI patient was used. There 
is no reason to assume causal donors are more or less likely to have missing informa-
tion than non-causal donors, especially since it is unknown which donors are causal. 
Therefore, for some TRALI patients the missing donor will be causal and for some it will 
be one of the innocent bystander donors. In the first case the total alloexposure of all 
donors for that patient will be underestimated. In the second case the total alloexposure 
of all donors for that patient will be overestimated. It can be shown mathematically that, 
in the applied analyses, these effects will cancel each other out perfectly and lead to a 
valid effect estimate.27
reference subjects: alloexposure status
Male and female donors have different alloexposure prevalences and the fractions of 
donations from male and female donors changed during the study period. Amongst 
the most important changes was the decision to exclude all plasma from female donors, 
donated after October first 2006, from transfusion. To correct for changes in fractions of 
donations from male and female donors, we first determined these fractions for each 
year and product type separately (as described below; for plasma donated in 2006 we 
also distinguished between donations before October first and donations on or after 
October first).
We then determined the alloexposure prevalence for male and female donors 
separately (as described below). Subsequently we calculated the fraction of donations 
from allo-exposed male donors by multiplying the year-of-donation-and-product-type-
specific fraction of donations by male donors with the fraction of alloexposure among 
male donors. The fraction of donations from female alloexposed donors was calculated 
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in the same way and these two fractions were added to estimate the total fraction of 
donations from alloexposed donors (i.e. which is also year of donation and product type 
specific).
The fraction of products from female donors was determined from complete records 
of all blood donations in the Netherlands. For each product type the national blood 
supply organization records were used to determine the exact numbers produced from 
donations by male and female donors. From these data the fraction of each product type 
donated by male and female donors was calculated, specified by year of donation. This 
included an average of 558,716 whole blood donations per year for red cells and buffy 
coat derived platelets and an average of 51,472 plasmapheresis donations per year for 
fresh frozen plasma. The fraction was matched by donation date rather than transfusion 
date, to allow for the large variations in storage time of fresh frozen quarantine plasma.
History of blood transfusion and pregnancy were determined as part of the Donor 
InSight study. This study was conducted by Sanquin Blood Bank, between April 2007 
and April 2009, to gain insight into characteristics and motivation of the Dutch donor 
population. Donors who were not permanently deferred at time of invitation for the 
Donor InSight study were eligible to take part in the study. About 50,000 randomly 
selected whole blood and plasma donors were invited to participate. Each month a 
random sample of active donors was selected from the donor population and invited. 
Donors received an information brochure and questionnaire by regular mail. Donors 
who agreed to participate in the Donor InSight study were asked to return the com-
pleted questionnaire by mail. The questionnaire also recorded information on blood 
transfusion and pregnancy history. The Medical Ethical Committee Arnhem-Nijmegen 
in The Netherlands approved the study.
The present report is based on data collected from April first 2007 until March 31st 
2008. During this year, a total of 24,179 donors were invited to participate, of which 
15,249 returned the questionnaire and gave informed consent for participation (re-
sponse 63.1%). A random sample of 1,500 donors was drawn from these 15,249 donors 
who returned the questionnaire. Donors were considered allo-exposed if they reported 
either one or more pregnancies, one or more blood transfusions, or both.
Of the 1,500 randomly drawn donors 279 had not donated blood in the last year and 
were not included in further analyses, since their donation frequency was zero. Amongst 
the remaining 1,221 a further 181 were excluded because their only donation was for 
safety testing purposes (n=10), because they only donated plasma for fractionation 
purposes (n=132), or because based on the donation code they could be identified 
as specifically selected to be non-transfused male donors (n=39). Alloexposure status 
among 1,040 donors was therefore used in the analyses. These 1,040 donors are a 
random sample of all normally donating donors and therefore represent the average 
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alloexposure status among donors donating products transfused to TRALI patients who 
only received products from routine donations.
Sanquin records were used to link the alloexposure status of each individual donor to 
the donation frequency of that donor. Numbers of donations from alloexposed donors 
were calculated by multiplying the numbers of alloexposed donors by their donation 
frequency. The fractions of products from alloexposed donors were then calculated 
for male and female donors separately. The average of these male and female specific 
fractions was subsequently calculated, weighted for the fractions of donations from 
male and female donors according to product type and year of donation (determined 
as described above).
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absTracT
background
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related 
mortality. To support the diagnosis of antibody mediated TRALI, HLA and HNA antibod-
ies are tested in involved blood donors. Identification of antibody positive donors is 
important as exclusion of these donors is part of preventative strategies against TRALI. 
We compared cellular-based versus bead-based techniques for diagnosis of antibody 
mediated TRALI.
study design and methods
All reported TRALI-cases in the Netherlands during a 5-year period were evaluated. Do-
nors were screened for the presence of HLA class I and II antibodies using both cellular-
based and bead-based techniques.
results
In total 100 TRALI-cases were reported of which 91 were fully tested. In 113 donors HLA 
antibodies were detected of which 84 were only detected by bead-based techniques, 
12 only by cellular-based tests and 17 by both assays. Antibody mediated TRALI was 
diagnosed in 44/91 of reported cases. Twenty-one (48%) of these cases would not have 
been identified using only cellular-based assays.
conclusion
Bead-based techniques show a higher sensitivity for detecting incompatible donors in 
TRALI-cases than cellular-based assays. These results suggest that the use of bead-based 
assays will result in a significant reduction of future TRALI reactions as more antibody 
positive donors will be excluded from future donations.
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inTroducTion
Transfusion-related acute lung injury (TRALI) is a serious, sometimes fatal complication 
of blood transfusion. It is the leading cause of transfusion related morbidity and mortal-
ity.1 TRALI is defined according to the Canadian Consensus Conference (CCC) criteria 
(Table 1) as the acute onset of hypoxemia (paO2/FiO2 ≤300 mmHg or saturation <90% on 
room air) with new or worsening bilateral infiltrates on the chest radiograph, occurring 
during or within 6 hours of a blood transfusion in the absence of circulatory overload.2-5 
Although in recent years the awareness of TRALI has been increasing, it is still misdiag-
nosed and underreported.6-8
TRALI has been attributed to two mechanisms of onset, the antibody and non-
antibody mediated TRALI.9 Antibody-mediated TRALI is caused by incompatibility 
between donor white blood cell (WBC) antibodies (human leukocyte antigens (HLA) 
class I or II or human neutrophil antigens) and patients’ white blood cells.10,11 Binding 
of these antibodies to their cognate antigens causes endothelial and neutrophil activa-
tion. These activated neutrophils sequester in the lungs, causing endothelial damage, 
capillary leakage and pulmonary edema. Non-antibody mediated TRALI is thought to 
be caused by pro-inflammatory mediators (e.g. biologically active lipids, soluble CD40 
ligand) which accumulate during storage of cell-containing blood products.12-14 Older 
blood products would therefore be more prone to cause TRALI.
TRALI diagnosis is based on clinical and radiographic findings; there is no pathog-
nomonic laboratory test to confirm the diagnosis. To identify antibody-mediated TRALI 
the clinical diagnosis is supported with laboratory investigations. All donors from blood 
products transfused to the patient within a period of 6 hours before the start of the 
TRALI symptoms are tested for HLA class I and II antibodies and HNA-antibodies. To es-
tablish incompatibility the patient is typed for HNA and HLA antigens and cross-matches 
between donor serum and patient leukocytes are performed. Donors are assigned in-
compatible and possibly causal if there is a positive cross-match or if specific antibodies 
against cognate antigens are found. Reporting and identifying possible causal donors 
Table 1. Definition transfusion-related acute lung injury (TRALI) according to the Canadian TRALI Consen-
sus conference and US National Heart, Lung and Blood Institute Definition.2-5
Suspected TRALI Acute onset within 6 hours of blood transfusion
PaO2 /FI O2 <300 mm Hg, or worsening of P to F ratio
Bilateral infiltrative changes on chest radiograph
No sign of hydrostatic pulmonary edema (pulmonary arterial occlusion pressure ≤18 
mm Hg or central venous pressure ≤15 mm Hg)
No other risk factor for acute lung injury
Possible TRALI Same as for suspected TRALI, but another risk factor present for acute lung injury
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of TRALI cases are keystones in the prevention of future TRALI cases as the implicated 
donors are excluded from future donations. However, as it can take several weeks before 
the results are known, they have no value in diagnosing an acute TRALI-reaction. Until 
recently the standard methods to detect white blood cell antibodies were cellular-based. 
These methods are very time-consuming and are dependent on highly skilled staff for 
obtaining reliable results. The proficiency to detect antibodies varies from 16.7 to 100% 
between different laboratories15 and recently it was reported that detection of HNA-
antibodies with bead-based assays is more reliable than detection with cellular-based 
assays.16,17
To investigate whether the use of bead-based techniques might improve the diagno-
sis of antibody mediated TRALI, we compared cellular-based techniques to bead-based 
techniques for detection of HLA antibodies in a series of 100 consecutively reported 
TRALI cases.
maTerials and meThods
Patient study population
All suspected cases of TRALI in the Netherlands reported to the Sanquin Blood Bank (the 
national blood supply organization) during a 5-year period (January 2005 till January 
2010) were evaluated as previously published.18 TRALI was diagnosed by the hospital 
medical personnel and subsequently reported to one of the transfusion consultants 
of the blood bank. All cases were additionally reviewed by physicians familiar with 
TRALI. Only cases fully meeting the consensus criteria for TRALI from the Canadian 
Consensus Conference (Table 1) were included and investigated for patient, donor and 
product characteristics. Data was analyzed by DvS and EB. Patient characteristics col-
lected included age, sex, admitting diagnosis (surgical vs non-surgical), and transfused 
blood components. All donors of blood products transfused within 6 hours before the 
development of TRALI were investigated, and donor variables reviewed included sex, 
age, parity, blood transfusions in past, and results of antibody testing. A donor involved 
in a TRALI case is designated as implicated when incompatibility was proven between 
donor antibodies and patient cells. When antibodies are not incompatible with patient 
antigens or in absence of these antibodies, the donor is flagged as associated with a 
TRALI case. Donors flagged two times as associated with a TRALI case are excluded from 
further donation in The Netherlands.
blood products
The patients were transfused with red blood cells (RBCs), platelets (PLTs), or fresh-frozen 
plasma (FFP). The RBCs were suspended in saline-adenine-glucose-mannitol (SAGM) ad-
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ditive solution (AS) and pre-storage leukoreduced (<1 × 106 white blood cells [WBCs]). 
The final product contained a mean volume of 20 mL of plasma, the mean total volume 
was 270  mL, and the mean hematocrit level was 0.57. The majority of PLT products 
transfused were pooled random-donor units (prepared from the buffy coats [BCs] of five 
donors). Pooled PLTs were pre-storage leukoreduced (<1 × 106 WBCs) and suspended in 
plasma or PLT AS (PAS II). The mean volume was 310 mL. Single-donor apheresis units 
were only used when HLA-compatible PLTs were needed. When indicated, RBCs and 
PLTs were washed or irradiated. FFP was derived from single-donor apheresis donations 
and contained fewer than 1  ×  106 WBCs. Since July 2007 only apheresis plasma from 
non-transfused male donors was used for FFP. The plasma was quarantined for at least 
6 months. The volume was approximately 325 mL. For all patients type of blood prod-
ucts transfused within 6 hours before the development of signs and symptoms were 
recorded.
laboratory tests
WBC-reactive antibodies were examined in all patients (in post-transfusion blood sam-
ples and, if available, in pre-transfusion samples) and in all donors of blood components 
transfused to patients within 6 hours preceding the development of TRALI.
Complement-dependent cytotoxicity (CDC) assay
All patients and donors were screened for HLA Class I antibodies using a standard 
complement-dependent cytotoxicity (CDC) assay against a panel of HLA Class I-typed 
donor lymphocytes.19 Serum to be tested was incubated with the lymphocytes and rab-
bit complement. If antibodies present in the serum bound to the cognate antigen on 
the lymphocyte, the complement cascade was activated, leading to cell death. By using 
fluorescent dyes, cell death was observed using microscopy and used as an indicator 
of the presence of HLA Class I antibodies. More than 20% cell death was considered as 
a positive reaction in the CDC technique. For the detection of HLA Class II antibodies a 
two-colored fluorescence test with a panel of HLA Class II-typed donor B-lymphocytes 
was used as described by van Rood et al.20
Bead-based screening assay
In addition, a flow cytometry bead-based screening assay for the presence of HLA Class I 
and II antibodies (FlowPRA, One Lambda, Inc., Canoga Park, CA) was used. In this assay 30 
individual beads for both HLA Class I and II were combined. Each bead was coated with 
purified HLA Class I or Class II antigens. Serum was incubated with the beads and stained 
with a FITC labeled anti-human IgG antibody. Class I and II beads were distinguishable 
on a flow cytometer by their different fluorescent properties. The percentage of beads 
showing a positive fluorescence represented the percentage panel reactive antibodies 
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(PRA). For HLA Class I PRA over 12% was considered positive. For HLA Class II this was 4%. 
If samples were positive by CDC and/or flow cytometry screening assay, the specificity of 
HLA Class I and II antibodies was determined using single antigen beads on the Luminex 
platform (Labscreen SA, One Lambda, Inc.). In this assay all individual beads were coated 
with one HLA Class I or II antigen. A phycoerythrin (PE)-conjugated anti-human IgG 
antibody was added. The luminex platform could identify the color-coded beads and 
PE-fluorescence emission at the same time. A cutoff for a positive Luminex test of 1000 
(normalized) mean fluorescence intensity was used. The cut off was based at a reference 
group of male non-transfused donors.
Lymphocyte immunofluorescence test (LIFT)
Lymphocyte-reactive antibodies were examined by the lymphocyte immunofluores-
cence test (LIFT) against two pools of five typed donor-lymphocyte suspensions each, 
according to Décary.21
HNA-antibodies
HNA-1a, -1b, -1c and -2a antibodies were examined by the granulocyte immunofluores-
cence test (GIFT) based on the method of Verheugt et al.22 Granulocytes from donors of 
known HNA genotypes were incubated with serum from the involved donors and sub-
sequently with FITC-labelled rabbit-anti-human IgG. The fluorescence observed under a 
fluorescence microscope was a measure for antibody activity. HNA-3a antibodies were 
examined by the granulocyte agglutination technique (GAT), according to Jiang and La-
lezari.23 The test serum was placed under oil in a microtiter tray. The typed granulocytes 
were added and the tray was incubated. The size of the aggregation and the proportion 
of cells participating were examined under an inverted phase microscope
Incompatibility testing
Incompatibility of antibodies found in the bead-based assays was tested by HLA ge-
notyping the patients using a polymerase chain reaction-based assay with sequence-
specific primers (Olerup SSP AB, Saltsjöbaden, Sweden) and/or sequence-specific 
oligonucleotides primers (One Lambda, Inc.) for HLA Class I and II. WBC incompatibility 
was also assessed by performing cross-matches between donor serum and patient’s 
lymphocytes in the CDC and LIFT. Donors were assigned incompatible if either a positive 
cross-match or specific antibodies against cognate antigens in the patient were found.
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resulTs
Trali-cases
In the 5-years period 100 cases of suspected TRALI reported to the Sanquin Blood Bank 
met all CCC criteria for TRALI. Of these 100 cases, 54 patients were males. Table 2 displays 
patient characteristics. Mean age of the patients was 55 years (range 2 to 89 years). Fifty 
patients had recent surgical treatment, 48 were classified as nonsurgical. In 2 cases the 
diagnosis at admittance was unknown. In 26 cases an alternative risk factor for ALI was 
present (possible TRALI according to CCC criteria for TRALI). Ninety-one of these cases 
were fully tested for donor antibodies and incompatibility (in the other 9 cases, either 
the donors could not be tested or there was no patient blood to test incompatibility, 
mainly because the patient had died). In the 91 fully tested cases a total of 451 blood 
products (RBCs, FFP, buffy coats or PLTs) were involved. The pooled PLTs were count for 
5 blood products, because 5 buffy coats were used and subsequently 5 different donors 
were involved. The mean number of blood products transfused during the 6-hour pe-
riod before the onset of TRALI was 4.96 (median 3, range 1-17). The overall male:female 
ratio of the donors was 1.8 (290:161). We found HLA antibodies in 113 donors (Table 3b) 
implicated in 62 of 91 TRALI cases. In 10 cases HNA-antibodies were detected. In 5 of 
these cases also HLA-antibodies could be found.
cdc/lifT versus bead-based techniques
Overall, in 62 (68%) of 91 fully tested TRALI cases donor antibodies were found in one 
or more donors using both CDC and bead-based techniques. The type of products 
transfused stratified for incompatible and compatible cases are presented in Table 3a. 
In the vast majority of cases HLA antibodies were detected solely by bead-based assays 
(Table 5). In 113 donors HLA antibodies were detected, 84 were detected by bead-based 
techniques; 17 by both cellular and bead-based assays. In 12 donors only cellular-based 
tests were positive, of which 7 had non-specific IgM (IgM antibodies without any identi-
fiable HLA-specificity) in the CDC, 3 had aspecific LIFT reactivity and 2 had specific HLA 
Table 2. Characteristics of patients implicated in TRALI reactions.
Patients (n=100)
Male sex (%) 54
Age, years (mean and range) 55 (2 – 89)
Diagnosis at admittance (%)
 Medical 48
 Surgical 50
Other/unknown 2
Survival (%) 79
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antibodies found in the CDC. Positive results in the CDC or LIFT were mostly not informa-
tive of the specificity of the HLA antibodies. In 103 donors (male:female=34:69) specific 
HLA antibodies were identified, only 2 of these antibodies were found by cellular-based 
assays only. There were 58 donors with HLA-I antibodies, 24 with HLA-II antibodies and 
21 with both HLA-I and II antibodies.
Table 3a. Products involved in antibody positive TRALI cases
Cases RBC BC FFP
Incompatible cases, (n) 44  - - - - - -
-Total products 131 98 76
-Products with antibodies  45 28 22
Compatible cases, (n) 18  - - - - - -
-Total products  38 25 15
-Products with antibodies  13  6  4
RBC= red blood cells, BC=buffy coat, FFP=fresh frozen plasma
Table 3b. HLA antibodies in products implicated in TRALI cases.
Cases Number of Donors
Male Female Total
Total donors involved 91 290 161 451
Total cases with antibodies 62 40 73 113
 Incompatible cases 44
 Incompatible antibodies — 16 43 59
 Compatible antibodies — 16 18 34
 Compatible cases 18
 Antibodies — 8 12 20
Table 4. General results of antibody testing in donors and patients
Number of Cases (%)
Total cases reported 100
Total cases fully tested 91 (100)
Total donor antibodies 62 (68.1)
 HLA-class I 58
 HLA-class II 24
 HLA-class I and HLA-class II 21
Patient and donor antibodies 26 (28.6)
Patient antibodies only 14 (15.4)
Incompatible cases 44 (48.4)
Compatible cases 18 (19.8)
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The use of bead-based techniques would have identified an additional 21 antibody-
mediated TRALI-cases compared to CDC based techniques only.
discussion
This study is the first to provide evidence that the sole use of cellular-based TRALI diag-
nostic techniques leads to under identification of incompatible donors in TRALI cases, 
resulting in under diagnosing of antibody-mediated TRALI. The main findings of this 
study are; 1) Bead-based techniques results in improved diagnosing of incompatible 
donors in antibody mediated TRALI reactions compared to cellular-based assays. 2) Use 
of bead-based assays for detection of leukocyte antibodies in blood donors will likely 
result in a significant reduction of TRALI as more donors implicated in TRALI will be 
excluded for future donations.
The aim of the current study was to compare the cellular-based technique to the 
bead-based technique in identifying donors responsible for TRALI cases. Surprisingly, 
the bead-based techniques identified 58% (34/59) more incompatible donors in a TRALI 
reaction and 48% more antibody-mediated TRALI cases. It is tempting to provide an ex-
planation. One explanation may be that the bead-based technique is not depending on 
the presence of a “first hit”. In contrast, the cell-based method uses typed lymphocytes 
from healthy donors. These healthy donors do not suffer from an underlying condition, 
which is most often the case in the patient developing TRALI. Previous studies have 
identified that HLA class antigen up-regulation occurs in the presence of an underlying 
condition.24,25 This is in line with the “two hit” hypothesis of TRALI in which the underly-
ing condition of the patient is the “first hit” and results in priming of the pulmonary en-
dothelium and neutrophils.12 The transfusion is the “second hit” and results in activation 
of the neutrophils and subsequently to leakage of the pulmonary endothelium resulting 
in pulmonary edema, i.e. TRALI. In the absence of the “first hit” there is no onset of TRALI. 
Hence, a blood product may be tested positive in cellular based techniques only when 
Table 5. Results of HLA antibody detection in donor plasma by cellular and bead-based techniques. Cel-
lular techniques include the CDC and LIFT.
HLA-antibodies
Cellular techniques Bead-based techniques Both Total
HLA-I 2 49 7 58
HLA-II — 22 2 24
HLA-I and HLA-II — 13 8 21
Other* 10 — — 10
Total 12 84 17 113
*Other antibodies included 7 aspecific IgM CDC cases and 3 aspecific LIFT cases
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the immune system is activated which is not the case as cells are obtained from healthy 
donors. The above mentioned hypothesis of a “two hit” model for antibody mediated 
TRALI has been confirmed in pre-clinical studies. In a mice model of MHC-I mediated 
TRALI, TRALI only occurred in the presence of a “first hit” using LPS.26 This was also con-
firmed in a rat model of antibody mediated TRALI using MHC-I antibodies.27 Recently 
the mechanism has also been tested and confirmed for other antibodies involved in 
antibody mediated TRALI such as HNA.28
Next to improved accuracy, bead-based techniques may also result in cost reduction. 
Cellular-based techniques are very time consuming. The CDC test requires 16 man-
hours. For the CDC test cell panels of 54 typed donor lymphocytes are necessary, which 
is costly to create and maintain these cell panels. A bead-based antibody screening 
assay takes only 4 hours, the kits used have lower costs compared to maintaining CDC 
test cell panels.
Although a recent meta-analysis showed that implementation of male-only donor 
strategies for high volume plasma products resulted up to a two third reduction of 
TRALI, accurate testing of involved donors in suspected TRALI cases remains a key stone 
in the further prevention of TRALI.29 Male donors still have 1-7% presence of HLA/HNA 
antibodies.30-32 Furthermore, RBC products still originate from both female and male 
donors. As only 10-20ml plasma is sufficient to induce antibody mediated TRALI,33 it is 
expected that introducing of bead-based techniques will result in better identification 
of incompatible donors in antibody mediated TRALI and subsequent prevention of 
future TRALI cases. Another precautionary measure to prevent TRALI is screening blood 
donors for HLA and HNA antibodies.34 Cellular-based tests are very labor-intensive and 
require highly skilled staff. For these reasons they are hardly appropriate for screening 
in blood donors. Bead-based assays are more suitable and possibly more effective for 
screening in large scale populations.
An important issue is that one could argue whether all incompatible antibodies found 
in the bead-based assay were causal for the TRALI reaction as we did not perform func-
tional test of the incompatibility. Based on retrospective studies, HLA-class I antibodies 
account for 14.3–26.7% of TRALI cases, HLA-class II antibodies 0.0–46.7% and HNA anti-
bodies for 16.7–28.6%.35 However, the majority of antibody-containing blood products 
do not cause TRALI in patients and case reports have shown that the presence of incom-
patible antibodies does not always result in the onset of TRALI.36-40 From this perspective, 
bead-based analysis may result in an overestimation of the causal relation for antibody 
positive donors in a TRALI case. However, in line with the threshold model it is unclear 
whether in, for example, critically ill patients, infusion of these incompatible antibodies 
would have resulted in onset of TRALI. Hence, we do not know what the threshold is 
for the onset of TRALI for a specific antibody and from this point of view all antibody 
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positive donors should be excluded. Indeed, drastic TRALI mitigation strategies which 
excluded all antibody positive donors have resulted in a two third reduction of TRALI.41-43
In conclusion, the use of bead-based techniques results in improved identification of 
incompatible donors in antibody-mediated TRALI compared to cellular-based assays. 
Our results suggest that the use of bead-based assays will result in a significant reduc-
tion of future TRALI reactions as more donors with HLA antibodies will be excluded of 
future donation.
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absTracT
background
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related 
mortality. In the past decade blood banks have implemented low-risk TRALI donor 
strategies, including a male-only donor policy for plasma-containing blood products 
to prevent onset of TRALI. We performed a meta-analysis to determine whether use of 
low-risk TRALI donor strategies for plasma indeed reduces onset of TRALI.
study design and methods
We searched MEDLINE and Cochrane Central Register of Controlled Trials from January 
1995 up to January 2013. Two reviewers independently extracted data on study char-
acteristics, methods, and outcomes. Primary endpoint was onset of TRALI. Subgroup 
analyses were performed for patient populations prone to develop TRALI and general 
patient populations.
results
Ten articles were included. Meta-analysis using a random-effects model taking into ac-
count all transfused products showed a significant reduction for the risk of TRALI after 
implementation of low-risk TRALI donor strategies (odds ratio [OR], 0.61; 95% confidence 
interval [CI], 0.42-0.88). Data from patient populations prone to develop TRALI showed 
a significant reduction of TRALI risk (OR, 0.51; 95%CI, 0.29-0.90), while data from general 
patient populations showed a similar non-significant trend (OR, 0.66; 95%CI, 0.40-1.09). 
Results were similar when taking only plasma products into account (OR, 0.62; 95% CI, 
0.42-0.92).
conclusion
The introduction of low-risk TRALI donor strategies for plasma-containing products 
results in a reduction of TRALI.
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inTroducTion
Transfusion-related acute lung injury (TRALI) is a life-threatening complication of blood 
transfusion. It causes high morbidity and is the leading cause of transfusion-related 
mortality for the past 5 years in the United States.1 TRALI is a clinical diagnosis and 
defined as a new episode of acute lung injury (ALI) occurring during or within 6 hours 
after a blood transfusion in the absence of hydrostatic edema.2;3 TRALI can be the result 
of a single event (e.g. transfusion), although most TRALI cases are postulated to be a 
‘two-event’ entity. The first event is related to the underlying condition of the patient 
(e.g., infection or surgery) that causes activation of the pulmonary endothelium, lead-
ing to the sequestration and priming of neutrophils in the lung. The second event is 
the transfusion of a blood product, which activates the primed neutrophils in the lung, 
causing endothelial damage, and subsequently TRALI.4
The transfusion factors can be divided into antibody- and non-antibody-mediated 
TRALI. Non-antibody-mediated TRALI is caused by transfusion of stored cell-containing 
blood products. Proinflammatory mediators that have accumulated during storage or 
the aged red blood cells (RBCs) and platelets (PLTs) themselves have been implicated 
in non-antibody-mediated TRALI.4-7 Antibody-mediated TRALI is caused by passive infu-
sion of antibodies, which causes neutrophil activation.8 The latter form of TRALI is the 
most prevalent type 9;10 and will be subject of the current meta-analysis. Antibodies are 
present in plasma-containing blood products. Plasma from female donors has been 
particularly implicated in the pathogenesis of TRALI.11-13 Donor leukocyte reactive an-
tibodies (HLA class I and II and anti-granulocyte [HNA] antibodies) are mainly found in 
(multiparous) female donors. This might be explained by alloimmunization during preg-
nancies.14 Therefore, plasma derived from male donors should less likely cause TRALI 
than plasma derived from women. In 2003, the National Blood Service in the United 
Kingdom was the first to implement a precautionary measure to reduce TRALI by the 
preferential use of plasma from male donors for transfusion.15 Nowadays, more blood 
collection organizations have taken similar measures (table 1). Most of them use only, or 
preferentially, plasma from male donors for single-donor plasma. Some blood collection 
organizations also implemented a (predominantly) male-only donor strategy for other 
high-volume plasma products such as PLT concentrates.17 However, the implementation 
of these low-risk TRALI donor strategies for plasma-containing blood products have seri-
ous consequences for the blood supply, in particular for the availability of AB plasma. 
So far, effects of these high-volume plasma donor policies have only been published in 
observational studies.15;18-26
To quantify the impact of low-risk TRALI donor strategies for plasma on the onset of 
TRALI, a meta-analysis of all trials on this topic since 1995 was performed.
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maTerials and meThods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
recommendations were used for this meta-analysis.27 We did not register our protocol.
study selection criteria
Selection strategy was to identify and review all studies that met the following criteria: 
observational controlled trials of transfusion, plasma, TRALI, and ALI.
search strategy
To identify literature in electronic databases, MEDLINE from January 1, 1995, through 
January 1, 2013, was searched, by using the following medical subject heading (MeSH) 
terms: blood transfusion, plasma, ARDS and ALI. The following text words were used: 
TRALI and transfusion related acute lung injury. To identify observational studies, the 
MeSH terms case-control study and retrospective study were added.
The Cochrane Library (2012), which contains the CENTRAL Database of Controlled 
Trials, the Database of Abstracts of Review Effectiveness, and the Cochrane Database of 
Systematic Reviews, was also searched.
In addition, the related articles feature of PubMed, which identifies related articles by 
using a hierarchical search engine that is not solely based on MeSH headings, was used. 
This search was completed with articles selected by two of the authors (AV and MM). 
Although search was also for non–English language citations, subsequent article review 
involved only English-language publications.
study selection
After all citations based on our search strategy were identified, two of the authors (AV 
and MM) independently reviewed each abstract to confirm eligibility. Eligible studies 
evaluated use of low-risk TRALI donor strategies for plasma and onset of lung injury and 
mortality. Low-risk TRALI donor strategies were defined as predominantly or male-only 
donor policy for plasma products, plasma from donors screened for absence of HLA and/
or HNA antibodies, and plasma from female donors without history of pregnancy. Both 
Table 1 Overview of different low risk TRALI donor strategies16
Low risk TRALI donor strategies
Donor deferral based on antibody screening
 Screening all donors for HLA and/or HNA antibodies
 Screening previously alloexposed donors for HLA and/or HNA antibodies
Donor deferral based on history of pregnancy or history of transfusion
Deferral of all female donors
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controlled and observational trials were considered eligible. If an abstract was selected 
as eligible, the same authors independently reviewed the respective article, if available, 
to confirm that it met inclusion criteria. To resolve discrepancies, the two reviewers either 
had to reach consensus or use a third reviewer (JB). Interobserver agreement for study 
selection was determined by κ, with a value above 0.80 indicating good agreement.
data extraction
Using a predefined data collection form, data from the studies to describe patient char-
acteristics, study methods, and study findings were extracted. All data were abstracted 
independently by each of the two primary reviewers and verified for accuracy by the 
third reviewer, again with discussion used to resolve differences among reviewers. Both 
primary reviewers were physicians with formal training in clinical epidemiology and 
biostatistics. Corresponding authors of included studies were requested by e-mail to 
provide missing data for the meta-analysis.
data synthesis and analysis
Primary endpoint was the effect of the introduction of a low-risk TRALI donor strategy 
for plasma-containing products on occurrence of TRALI. The secondary endpoint was 
the effect of the introduction of a low-risk TRALI donor strategy for plasma-containing 
products on mortality among TRALI patients. Two subsets were analyzed: 1) the group 
of studies with data from local registries (patients prone to develop TRALI) and 2) the 
group of studies with data from nationwide registries (general patient population). 
As patients often receive different types of blood products, we analyzed the effect of 
TRALI risk reduction strategies for all transfused products (denominator, total number 
of transfusions; and numerator, all TRALI cases); in addition, we assessed the effects of 
TRALI risk reduction strategies on plasma-induced TRALI (denominator, total number of 
plasma transfusions; and numerator, plasma-induced TRALI cases).
The percentage of agreement before discussion among reviewers in study selec-
tion, study design, and data abstraction was measured. For data synthesis, evidence 
tables were constructed, to present data separately for the primary outcome variable, 
onset of TRALI per transfused blood product, and the secondary outcome variable, 
30-day mortality. Furthermore, data were presented based on study population, for 
example, at-risk patients (intensive care unit and surgery) or general hospital or region 
population.
The study design was classified as a randomized clinical trial, cohort study (prospec-
tive, retrospective, or historical control), case-control study, or outcomes study (cross-
sectional).
The methodologic quality of eligible studies was assessed using the modified 
Newcastle-Ottawa scale, a validated instrument designed to evaluate the quality of 
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observational studies in systematic reviews and meta-analyses.28 The quality of cohort 
studies and case-control studies was assessed separately. Methodology was evaluated 
in three domains: selection of study population, comparability of study groups, and the 
quality of outcome assessment. The kappa (κ) statistic was used to assess inter-observer 
agreement on study quality and a value above 0.80 was defined as good agreement.29
statistical analysis
The meta-analysis was performed with a random effects model.30 A random-effects 
model, instead of a fixed-effects model, was chosen to take into account heterogeneity 
of the studies. The common study characteristics are the incidence of TRALI cases for 
the total number of blood products transfused. Effect sizes are expressed as odds ratio 
(OR) and their 95 % confidence intervals (CIs). The odds is the number of TRALI cases by 
the number of transfused products in a defined context. An OR lower than 1 expresses 
a protective effect of a low-risk TRALI donor strategy for plasma products to prevent 
onset of TRALI. An OR higher than 1 shows a protective effect against TRALI of transfused 
products in the period before the introduction of a male-only donor policy. Heterogene-
ity was expressed by the chi-square test. A cutoff p value of 0.1 was used to consider 
heterogeneity. A high p value suggests that the heterogeneity is insignificant. Analysis 
were performed with computer software (R: A language and environment for statistical 
computing. R Core Team, 2013, http://www.r-project.org/).31
resulTs
study selection
Our predefined search strategy identified 118 records after removal of duplicates. 
After titles were reviewed, 53 citations were excluded and an additional 28 were ex-
cluded based on the abstract. Of 37 full-text articles, 10 studies were considered eligible 
(Table 2) and 27 studies were excluded after detailed review. An overview of the search 
is presented in Fig. 1. Interobserver agreement for study selection was good (κ = 0.84).
study characteristics
No randomized controlled trials were found on the effect of a low-risk TRALI donor 
strategy for plasma products on the onset of TRALI. Therefore, we only included obser-
vational studies. Of these, two studies were prospective.22,23 The remaining eight stud-
ies had a retrospective design. Five studies were carried out within national registries 
using passive reporting of TRALI.15,19-21,25 Four studies were carried out in various high-
risk TRALI populations (e.g., intensive care and surgery patients) and in these studies 
TRALI was actively screened for.22-24,26 One study was carried out in the general hospital 
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patients, but using passive reporting.18 All authors used Canadian Consensus Criteria 
to diagnose TRALI.2,32 In four studies data were also collected before 2004, the year of 
establishment of the Canadian Consensus Criteria.15,21,25,26 Of these studies, one used 
American-European consensus criteria for ALI within 6 hours of transfusion26 and the 
second defined TRALI cases as “acute dyspnea with hypoxia and bilateral pulmonary 
infiltrates occurring during or in the 24 hours after transfusion, with no other apparent 
cause”.15 The remaining two studies retrospectively applied the Canadian Consensus 
Criteria.21,25 The majority of the included studies were able to implement a 95% to 100% 
male-only plasma donation policy. Two studies used, in addition to male-only plasma, 
plasma from female donors without history of pregnancy or without HLA and/or HNA 
antibodies.20,23 Four studies reported implementation of a male-only donor strategy for 
PLT products, in addition to a male-only donor strategy for plasma products, as these 
are high-plasma-volume products as well.15,19,21,26 Detailed characteristics of included 
studies are shown in tables 2 and 3.
methodological quality
The methodological quality of cohort studies is summarized in table  4 and of case-
control studies in table  5. Quality assessment revealed that risk of bias of patient 
selection was low. However, included studies were heterogeneous regarding TRALI 
surveillance, using passive or active reporting. In addition, in studies carried out within 
	  
HOOFDSTUK	  6	  
Figur 1 
 
	  
	  
Figuur	  2	  
figure 1: inclusion flow. Number of articles identified and process for inclusion in the meta-analysis.
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national registries possibly not all transfused patients were observed for the minimum 
of 6 hours, which may have resulted in underreporting of TRALI. However, this possible 
disadvantage was applicable for both periods, before and after implementation of TRALI 
risk reduction strategies. None of the nationwide studies corrected for confounding that 
may have been a possible source of bias. Blinded endpoint assessment was carried out 
in seven studies, leaving the possibility of interpretation bias in the other 3 studies.15,19,20 
Interobserver agreement for the quality assessment was good (median κ = 0.89 [range 
0.40 to 1.0]). Heterogeneity was assessed using I2 test. Heterogeneity was high (p<0.01) 
for all studies combined and low for predefined subgroup analysis (p>0.1).
meta-analysis on the risk of Trali
All TRALI cases
The effect of a low-risk TRALI donor strategy for plasma-containing products on the 
occurrence of TRALI for all transfused products in all studies is summarized in Fig.  2. 
Figures 3 and 4 show the effect of a low-risk TRALI donor strategy for plasma-containing 
products for high-risk populations and from nationwide registries, respectively. Four 
studies showed an association between the introduction of a low-risk TRALI donor 
strategy for plasma and a reduction of TRALI risk.18-20,23 In five studies there was a 
Table 3a. Transfusion data of cohort studies reporting transfused units
Reference TRALI cases  Total units 
transfused
PLASMA 
transfused
Platelets 
transfused
Red blood cells 
transfused
Before After Before After Before After Before After  Before After
Wright26 37 14 2917 1750 1026 629 131 91 1760 1030
Vlaar24 17 6 1350 485 174 135 88 25 1088 325
Nakazawa22 3 2 1596 1480 467 424 545 556 584 500
Arinsburg18 9 1 227913 233685 47756 52230 50041 50143 130116 131312
Toy23 23 10 89321 123731 NA NA NA NA NA NA
NA=not available
Table 3b. Transfusion data of cohort studies reporting distributed units
Reference TRALI cases Total units distributed PLASMA 
distributed
Platelets 
distributed
Red blood cells 
distributed
Before After Before After Before After Before After Before After
Chapman15 58 12 16550000 5897000 1874000 634000 1265000 518000 13411000 4745000
Eder19 58 127 8320437 33810762 1664598 6695037 637751 3172097 6018088 23943628
Wiersum25 68 31 4067000 1377000 545000 183000 279000 98000 3243000 1096000
Lin21 105 31 7633560 2364400 1648400 479050 638020 218330 5347140 1667020
Funk20 44 4 12170000 6200000 2360000 1080000 880000 490000 8930000 4630000
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figure 2. meta-analysis for the onset of Trali expressed over all products transfused before and 
after introduction of a low risk Trali donor strategy for plasma containing products. Effect sizes are 
expressed as Odds ratio and their 95 % confidence intervals. The Odds is the number of TRALI cases by the 
number of transfused products. An Odds ratio lower than one expresses a protective effect against TRALI 
of products transfused in the period after the introduction of a low risk TRALI donor strategy for plasma.
	  
	  
Figuur	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figure 3. meta-analysis for the onset of Trali in at risk patient populations expressed over all prod-
ucts transfused before and after introduction of a low risk Trali donor strategy for plasma contain-
ing products. Effect sizes are expressed as Odds ratio and their 95 % confidence intervals. The odds is the 
number of TRALI cases by the number of transfused products. An Odds ratio lower than one expresses a 
protective effect against TRALI of products transfused in the period after the introduction of a low risk 
TRALI donor strategy for plasma.
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trend to TRALI risk reduction after introduction of a low-risk TRALI donor strategy for 
plasma.15,21,22,24,26 TRALI risk was unaffected in one study.25
Pooled data of all studies showed a significant reduction for the risk of TRALI after 
implementation of a low-risk TRALI donor strategy for plasma-containing products (OR, 
0.61; 95%CI, 0.42-0.86).
Subgroup analysis revealed that data from local registries showed a significant reduc-
tion of TRALI risk (OR, 0.51; 95%CI, 0.29-0.90). Patients in local registries consisted of criti-
cally ill patients24 and patients undergoing major surgery22,26. As confirmed by one of the 
included studies23 these patients are more prone to develop a TRALI reaction compared 
to a general patient population that also includes outpatients. Data from nationwide 
registries (general patient population) showed only a tendency toward protection of a 
low-risk TRALI donor strategy for plasma containing products against TRALI (OR, 0.66; 
95%CI, 0.40-1.09).
Plasma-induced TRALI
Included studies implemented different TRALI risk reduction strategies, which also af-
fected TRALI risk associated with other products than plasma. Therefore, we performed 
an additional subgroup analysis to assess the effect of risk reduction strategies on 
Figuur	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figure 4. meta-analysis for the onset of Trali in general patient populations expressed over all 
products transfused before and after introduction of a low risk Trali donor strategy for plasma con-
taining products. Effect sizes are expressed as Odds ratio and their 95 % confidence intervals. The odds is 
the number of TRALI cases by the number of transfused products. An Odds ratio lower than one expresses 
a protective effect against TRALI of products transfused in the period after the introduction of a low risk 
TRALI donor strategy for plasma.
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plasma-induced TRALI. Nine of 10 included studies provided data on plasma-induced 
TRALI15,18-22,24-26. The pooled effect of a low-risk TRALI donor strategy on occurrence of 
TRALI per transfused unit of plasma is shown in Fig. 5. Figures 6 and 7 summarize the ef-
fect of low-risk TRALI donor strategy on plasma-induced TRALI in high-risk populations 
and from nationwide registries, respectively. Data for plasma-induced TRALI showed 
a similar pattern as the data for all transfused products. Plasma-induced TRALI was 
significantly reduced after introduction of a low-risk donor strategy (OR, 0.62; 95% CI, 
0.42-0.92). Patients from local registries (prone to develop TRALI) experienced a signifi-
cant risk reduction (OR, 0.51; 95% CI, 0.31-0.83), while data from nationwide registries 
(general patient population) showed a tendency to reduced risk of plasma-induced 
TRALI (OR, 0.69; 95% CI, 0.42-1.13).
meta-analysis on mortality
Data on 30-day mortality of the total cohort were only available from two studies.24,26 
Both studies showed a non-significant reduction of mortality of the cohort of transfused 
patients after implementation of a low-risk TRALI donor strategy for plasma products 
(43% before vs. 35% after and 43% before vs. 23%, NS, respectively). As there were 
Figuur	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figure 5. meta-analysis for the onset of plasma-induced Trali expressed over all units of plasma 
transfused before and after introduction of a low risk Trali donor strategy for plasma products. 
Effect sizes are expressed as Odds ratio and their 95 % confidence intervals. The odds is the number of 
plasma-induced TRALI cases by the number of transfused units plasma. An Odds ratio lower than one ex-
presses a protective effect against TRALI of plasma transfused in the period after the introduction of a low 
risk TRALI donor strategy for plasma containing products.
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figure 6. meta-analysis for the onset of plasma-induced Trali in at risk populations expressed over 
units of plasma transfused before and after introduction of a low risk Trali donor strategy for plas-
ma products. Effect sizes are expressed as Odds ratio and their 95 % confidence intervals. The odds is the 
number of plasma-induced TRALI cases by the number of transfused plasma. An Odds ratio lower than one 
expresses a protective effect against TRALI of plasma transfused in the period after the introduction of a low 
risk TRALI donor strategy for plasma containing products.
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figure 7. meta-analysis for the onset of plasma-Trali in general patient populations expressed over 
units of plasma transfused before and after introduction of a low risk Trali donor strategy for plas-
ma. Effect sizes are expressed as Odds ratio and their 95 % confidence intervals. The odds is the number of 
plasma-induced TRALI cases by the number of transfused plasma. An Odds ratio lower than one expresses 
a protective effect against TRALI of plasma transfused in the period after the introduction of a low risk TRALI 
donor strategy for plasma containing products.
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only two studies no meta-analysis was performed on these data points. As antibody-
mediated TRALI is suggested to be the most severe form of TRALI it can be hypothesized 
that reducing antibody-mediated TRALI would also result in a reduction of mortality 
among TRALI patients. Data on 30-day mortality among TRALI patients were available 
from four studies.23-26 None of the studies showed a significant reduction of 30-day 
mortality among TRALI patients after the introduction of a low-risk TRALI donor strategy 
for plasma-containing products. Pooling of data from these four studies showed a trend 
to a reduction of mortality among TRALI patients after introduction of a low-risk TRALI 
donor strategy for plasma containing products (OR, 0.69; 95%CI, 0.27-1.75). An overview 
of the effect of introduction of a low-risk TRALI donor strategy for plasma-containing 
products on mortality among TRALI patients is given in Fig. 8.
discussion
This study is the first meta-analysis on the impact of low-risk TRALI donor strategies for 
plasma on the onset of TRALI. The main findings of this study are; 1) Implementation of a 
low-risk TRALI donor strategy for plasma-containing products, mainly male-only donor 
Figuur	  8	  
	  
figure 8. meta-analysis for mortality among patients developing Trali before and after introduc-
tion of a low risk Trali donor strategy for plasma containing products. Effect sizes are expressed as 
Odds ratio and their 95 % confidence intervals
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policies, results in a significant reduction of onset of TRALI (OR, 0.61; 95%CI, 0.42-0.88). 2) 
Introduction of a low-risk TRALI donor strategy for plasma-containing products results in 
a trend toward a reduction of 30-day mortality among TRALI-patients (OR, 0.69; 95%CI, 
0.27-1.75). 3) At risk patient populations seem to benefit most from the introduction of 
a low-risk TRALI donor strategy for plasma products.
Our study is able to confirm that the use of a low-risk TRALI donor strategy such as a 
male-only donor policy for plasma indeed results in a reduction of TRALI. The majority 
of TRALI cases, up to 89%, are thought to be antibody-mediated TRALI, caused by the 
passive infusion of donor leukocyte-reactive antibodies, present in plasma-containing 
blood products.10 These antibodies are mainly induced by pregnancies and blood 
transfusions.14 This was the basis for the hypothesis that the use of plasma from non-
transfused male donors would minimize the antibody-mediated TRALI. Although this 
precautionary measure is effective it has serious consequences for the blood supply as 
the number of (potential) plasma donors is decreased by half, leading to a shortage of 
donors. In particular, a shortage in the availability of group AB plasma for transfusion is 
a serious concern19,21. From this point of view some countries introduced a preferentially 
male plasma donor strategy, as it was not feasible to use male-only plasma.15 It should 
be noted that using a male-only donor plasma policy does not totally prevent antibody-
mediated TRALI. First of all approximately 1% of the male donor population have 
antibodies.33 Second, PLT products are also high-plasma-volume products. The plasma 
added to the pooled plasma does not originate from male-only plasma in all countries. 
Third, RBCs are suspended in an additive solution. Although the final product contains 
only a mean volume of 10 to 20 mL of plasma, RBCs are also known to be implicated in 
TRALI.13,34 Fourth, not all countries exclude male donors who have a previous history of 
blood transfusion themselves from donating blood.35 Of note, an association between 
previous transfusions and the development of alloreactive antibodies has not unequivo-
cally been demonstrated.33 The above-mentioned reasons also partly explain residual 
TRALI cases in included studies.15,18-22 In addition, residual TRALI cases were reported to 
be caused by the use of group AB plasma from female donors.19,21
Theoretically, to completely minimize the risk of antibody-mediated TRALI, all donors 
should be screened for HLA and/or HNA antibodies and positive donors should be 
excluded for all blood products containing plasma, regardless the amount of plasma. 
Indeed, some blood collection organizations have implemented antibody screening for 
all donors or all female donors.36 This results in less donor loss, but accounts for higher 
costs and is very labour intensive. In addition, the occurrence of HNA antibodies may 
not be linked to pregnancy or sex. Therefore, further research is warranted before donor 
antibody-screening can be advocated.
There are alternatives that might be equally effective. Other countries (e.g. Norway, 
Finland, France) use pooled solvent/detergent plasma (S/D plasma) instead of single-
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donor plasma. Pooling has the advantage that it reduces the possible antibody load 
by dilution and by neutralizing antigens in the plasma pool, which minimizes the risk 
of TRALI.37 The countries that use pooled S/D plasma claim that they do not see TRALI 
reactions associated with this product. Another approach could be to ask the donors for 
a history of pregnancies and blood transfusions and subsequently test these donors for 
HLA and HNA antibodies. This method is a reliable predictor of HLA allo-immunisation.38 
It has been suggested, however, that this method may neglect potential HLA- and/or 
HNA-positive donors as many pregnancies end in the first weeks after conception, while 
women were not even aware of a pregnancy. Of note, no association was found between 
early miscarriages and occurrence of alloimmunisation of donors.33 Also, donors are not 
always aware of receiving blood transfusions as they are sometimes given during an 
operation without notification afterward.
The introduction of a low-risk TRALI donor strategy for plasma-containing products 
seemed to reduce 30-day mortality among patients developing TRALI. However, the 
observed reduction in mortality was only a trend that can possibly be explained by small 
number of studies and patients included. An explanation for mortality reduction among 
TRALI patients is tempting. Antibody-mediated TRALI is reported to induce a more 
severe form of TRALI compared to non-antibody-mediated TRALI.39,40 We hypothesize 
that as a result of a low-risk TRALI donor strategy for plasma-containing products, the 
frequency of antibody-induced TRALI is reduced, hereby contributing to a reduction in 
mortality among TRALI patients.
Data from our meta-analysis showed that the implementation of a low-risk TRALI do-
nor strategy for plasma had the highest impact among at-risk patient populations such 
as critically ill and surgery patients. This may be well explained by the threshold model 
of TRALI.41 In this model a threshold must be overcome to induce a TRALI reaction. Fac-
tors that determine the threshold are the predisposition of the patient that determines 
priming of the lung neutrophils and the ability of the mediators in the transfusion to 
cause activation of primed neutrophils. A strong antibody-mediated response can cause 
severe TRALI in an otherwise “healthy” recipient. When activation status is too low, it 
is possible that priming factors in the transfusion are not strong enough to overcome 
the threshold. This concept has been proven in animal models.42-44 This model explains 
why a low-risk TRALI donor strategy for plasma has limited effect in the general patient 
population as they have no severe underlying condition to overcome the threshold. 
In this population a high volume of antibodies or a strong antibody-antigen match is 
needed to overcome the threshold for onset of TRALI.23
Our study has several limitations. First of all there are no randomized controlled trials 
on the effect of a low-risk TRALI donor strategy for plasma on the onset of TRALI. It is 
also not expected that after the implementation of a low-risk TRALI donor strategy for 
plasma in many countries a randomized controlled trial will follow. The observational 
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nature of the studies and reliance on spontaneous reporting to the blood collection 
organizations or the nationwide registries (which may be far from complete) may have 
introduced bias. However, this bias would apply equally to the before and after period.
Second, implemented donor policies were not fully equal among all studies. Not all 
studies were able to achieve a 100% male-only donor policy for plasma due to scarcity 
of products with a certain blood group. Some studies reported the implementation of a 
male-only PLT policy in addition to a male-only donor plasma policy. Others also report 
the introduction, next to male-only plasma, of plasma from female donors without a 
history of pregnancy or without HLA and/or HNA antibodies. However, all implemented 
policies assume the same underlying mechanism of excluding (potential) HLA- or HNA-
positive plasma donors to prevent antibody-mediated TRALI.
Third, some of the studies included TRALI patients before the consensus criteria for 
TRALI from the Canadian Consensus Conference in 2004 were established.2,32 Before that 
year there were no universal criteria for TRALI, and TRALI was most likely underreported. 
However, this will rather give an underestimation of the effect of the low-risk TRALI 
donor strategy for plasma, as the period before 2004 is included in the before group. 
Fourth, heterogeneity was high for all studies combined and low for subgroup analysis. 
This can be explained by differences in population and observation period of included 
studies. The random-effects model used in our study provides an average effect and in 
this way controls for variation in studies included. From this perspective we believe that 
the higher heterogeneity in the total group analysis has no or limited impact on our 
results and conclusions.
In conclusion, this is the first meta-analysis on the effect of implementation of a 
low-risk TRALI donor strategy mainly based on a male-only donor policy for plasma-
containing products to prevent TRALI. This study shows that introduction of a low-risk 
TRALI donor strategy for plasma-containing products reduces the onset of TRALI, espe-
cially in high-risk patient populations. Furthermore, there is a tendency that reduction of 
antibody-mediated TRALI results in a lower mortality rate among TRALI patients.
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summary
Transfusion-related acute lung injury (TRALI) is a serious complication of blood transfu-
sion, which causes serious morbidity and is the leading cause of transfusion-associated 
mortality according to the FDA. The majority of TRALI cases (up to 89%) are thought to 
be antibody-mediated TRALI, caused by the passive infusion of white blood cell (WBC)-
reactive antibodies, present in plasma-containing blood products. This thesis focused 
on the role of donor WBC-reactive antibodies in TRALI, and the translation to preventive 
strategies
Chapter 2 describes an observational study of all reported TRALI cases meeting the 
Canadian Consensus Conference criteria for TRALI in the Netherlands in a 2.5-year pe-
riod (January 2005 through July 2007). A total of 49 patients met all criteria for TRALI. 
Clinical and laboratory features of these cases were described. All patients and donors 
were screened for HLA Class I and II, and granulocyte antibodies. There was a high 
morbidity and mortality. Seventy-eight percent of the patients were admitted to the 
intensive care unit or needed mechanical ventilation, and 10 patients died. High-volume 
plasma products (fresh-frozen plasma [FFP] and/or platelets in plasma) were involved in 
61% of the cases. The remaining patients received red blood cells only. White blood cell 
reactive antibodies in one or more involved donors were found in 73% of cases, with 
proven incompatibility in 21 of 44 (48%) investigated cases. Possible TRALI cases (with 
an alternative risk factor for acute lung injury) had significantly lower incompatibility 
rates compared to TRALI cases, 18% versus 58% (p = 0.036). In the 21 alloimmune cases, 
a total of 31 implicated donors were found. Female FFP products were involved in 57% 
of proven alloimmune cases and would theoretically be prevented using male-only FFP.
It is generally believed that the majority of TRALI cases are caused by female donors. In 
chapter 3 we aimed to examine the relation between female donors and the occurrence 
of TRALI by performing an international, multicenter case-referent study. TRALI patients 
who received blood products only from donors of a single sex were compared to a 
reference population. The observed sex distribution among the donors of these TRALI 
patients was compared to the expected sex distribution. Eighty-three TRALI patients 
who received transfusions from unisex donors were included. The relative risk (RR) of 
TRALI after a transfusion from female donors among red blood cell (RBC) recipients was 
1.2 (95% confidence interval [CI],0.69-2.1). Among plasma-rich blood product recipients 
the RR was 19 (95% CI, 1.9-191). This indicates that the role of female donors in TRALI 
cases caused by RBCs is negligible.
WBC-reactive antibodies are mainly found in alloexposed donors. Alloexposure is 
the exposure of the immune system to allogeneic cells or tissues (occurring through 
pregnancy, transfusion of blood components or transplantation). In chapter 4 we aimed 
to quantify the contribution of alloexposed donors to the occurrence of TRALI caused by 
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plasma-poor and plasma-rich products. A case-referent study was performed, data on 
alloexposure status of all 223 donors involved in TRALI cases was compared to informa-
tion on alloexposure status in the total donor population (the expected status). Fifty-one 
percent of all TRALI cases could have been prevented by deferral of alloexposed donors 
(population-attributable risk was 51% [95% CI, 14-88%]). In the 19 TRALI patients who 
received exclusively plasma-poor blood products, alloexposure of the donors was not 
associated with TRALI. In conclusion, alloexposed donors conferred an increased risk of 
TRALI in recipients of plasma-rich blood products, but not in recipients of plasma-poor 
products
To support the diagnosis of antibody mediated TRALI, WBC-reactive antibodies are 
tested in involved blood donors. Identification of antibody positive donors is important 
as exclusion of these donors is part of preventative strategies against TRALI. In chapter 5 
we investigated whether the use of bead-based techniques might improve the diagno-
sis of antibody-mediated TRALI. We compared cellular-based techniques to bead-based 
techniques for detection of HLA-antibodies in a series of 91 consecutively reported TRALI 
cases meeting the Canadian Consensus Conference criteria for TRALI. In 113 donors HLA 
antibodies were detected of which 84 were only detected by bead-based techniques, 
12 only by cellular-based tests and 17 by both assays. Antibody mediated TRALI was 
diagnosed in 44/91 (48%) of reported cases. Twenty-one (48%) of these cases would not 
have been identified using only cellular-based assays. In conclusion bead-based tech-
niques show a higher sensitivity for detecting incompatible donors in TRALI-cases than 
cellular-based assays. These results suggest that the use of bead-based assays will result 
in a significant reduction of future TRALI reactions as more antibody positive donors will 
be excluded for donation.
Antibody-mediated TRALI is the most prevalent type of TRALI. WBC-reactive antibod-
ies are mainly found in (multiparous) female donors. Therefore plasma derived from 
male donors should less likely cause TRALI than plasma from female donors. In the past 
decade blood banks have implemented low-risk TRALI donor strategies to prevent onset 
of TRALI. Most of these strategies are based on using only, or preferentially, plasma from 
male donors for single-donor plasma or deferral of donors based on history of preg-
nancy or transfusion. In chapter 6 a systematic review and meta-analysis was performed 
to further strengthen evidence for these low-risk TRALI donor strategies. Ten articles 
were included in the meta-analysis. The meta-analysis showed that the implementation 
of low-risk TRALI donor strategies reduced the onset of TRALI (OR, 0.61; 95%CI, 0.42-
0.88). Subgroup analysis showed that the effect was most clear in patient populations 
more prone to develop TRALI (e.g., critically ill patients and patients undergoing major 
surgery [OR, 0.51; 95%CI, 0.29-0.90]). The effects in general patient populations showed 
a similar non-significant trend (OR, 0.66; 95%CI, 0.40-1.09).
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general discussion
The role of donor antibodies in antibody mediated Trali
The research presented in this thesis focused on the role of donor white blood cell 
(WBC)-reactive antibodies in TRALI. The majority of TRALI cases are thought to be 
antibody-mediated TRALI, caused by the passive infusion of WBC-reactive antibodies, 
present in plasma-containing blood products.
We found WBC-reactive antibodies in a series of 49 TRALI patients in 73% of the cases, 
with proven incompatibility in 21 of 44 (48%) investigated cases. In our larger study 
of 91 fully tested TRALI cases this percentage was confirmed. Reported incidences of 
WBC-reactive antibodies in TRALI cases ranged from 25% to 89%.1-4 Only a few studies 
have attempted to correlate antibodies in the donor with antigens in the patient.1,5-7 In-
compatibility was demonstrated in 59% to 87.5% of these cases. We found a significant 
difference between the TRALI group and the possible TRALI group (with an alternative 
risk factor for ALI). In the TRALI group incompatibility was demonstrated in 58% of the 
cases, while in the possible TRALI group this was only 18%. It is possible that a different, 
non-antibody mechanism causes TRALI in the possible TRALI cases. Another explanation 
could be that in possible TRALI cases onset of TRALI follows a threshold model. When the 
“first hit”, the underlying condition of the patient, is strong enough only a small amount 
of antibodies (below the cut off ) may already result in TRALI. Furthermore incompatibil-
ity is often tested weeks after the onset of TRALI when the underlying condition of the 
patient has resolved and the immune system has come to rest. Incompatibility testing 
may subsequently be false negative.
The previously reported incompatibility rates are higher than the overall 48% incom-
patibility we found.1,5-7 Two of these published studies had only small numbers of TRALI 
cases, these might include only TRALI cases without alternative risk factor.5,6 Three of the 
4 series were published before the establishment of the Canadian Consensus Confer-
ence criteria for TRALI. Another explanation may be that there is a publication bias in 
favor of series with high incompatibility rates.
WBC-reactive antibodies are induced by previous exposure to alloantigens. These 
alloexposures occur either through pregnancies or through blood transfusions and 
transplantations. As a consequence WBC-reactive antibodies are mainly found in (multi-
parous) female donors.8-11 In our international case-referent study we found that the risk 
of TRALI was increased among recipients of plasma-rich products (relative risk [RR] 19), 
but not among recipients of red blood cells (RR 1.2). The percentage of cases preventable 
by the exclusion of female donors was 7.0% for RBC recipients and 86% for recipients 
of plasma-rich blood products. These findings suggest that the majority of TRALI cases 
caused by plasma-rich products are preventable by the exclusion of female donors, 
whereas in TRALI caused by RBC transfusions the role of female donors is marginal. The 
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minimal amount of residual plasma, which might trigger TRALI, is not known. Possibly 
the volume of residual plasma in RBC’s is in general insufficient to cause TRALI. However, 
it is known that WBC-reactive antibodies present in RBC transfusions can cause TRALI.12 
We performed a systematic review of the literature to summarize the direct effect of the 
relation between female donors and TRALI. We found six studies on this topic.13-18 None 
of these six publications investigated the difference between plasma-rich and plasma-
poor products.
diagnosing Trali
The diagnosis of TRALI is based on clinical and radiographic findings, there is no 
pathognomonic laboratory test for TRALI. Antibody testing is only supportive in diag-
nosing TRALI. It takes weeks to months before the results of antibody testing are known. 
However the detection of WBC-reactive antibodies in involved donors is the keystone 
in diagnosing antibody-mediated TRALI. We found that bead-based techniques are 
more proficient in detecting these antibodies in donors involved in TRALI reactions 
than cellular-based assays. This leads to deferral of more donors and probably in a 
reduction of future TRALI reactions. An important issue is whether all incompatible 
antibodies found in the bead-based assay were causal for the TRALI reaction as we did 
not perform functional test of the incompatibility. Case reports have shown that the 
presence of incompatible antibodies does not always result in the onset of TRALI.19-22 
These observations gave rise to the hypothesis that TRALI might follow an “threshold 
model”.23 The threshold is formed by the level of priming of lung neutrophils and the 
ability of the mediators in the blood product (e.g. WBC-reactive antibodies) to activate 
these primed neutrophils. TRALI may develop in an (relatively) healthy person as long as 
the antibody titer is strong enough to overcome the threshold. Contrary, low antibody 
titers might be able to induce TRALI in patients with an underlying condition (e.g. sepsis, 
haematological malignancy). Therefore, it is important to trace and exclude all donors 
with WBC-reactive antibodies irrespective of titer concentrations, as the critical level is 
not known. This threshold model was supported by in vivo TRALI mouse models. Looney 
et al showed that exposure to pathogens might lower the threshold in mice.24 Vlaar and 
co-workers showed that mechanical ventilation lowered the threshold in a HLA-class I 
antibody mouse model.25
International guidelines and standardization of antibody screening assays is necessary 
to further elucidate the contribution of WBC-reactive antibodies in the pathogenesis of 
(antibody-mediated) TRALI.
Prevention strategies of antibody-mediated Trali
In 2003 the United Kingdom was the first to implement a transfusion policy to use 
predominantly plasma from male donors for the production of high plasma volume 
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blood products. Nowadays several countries have taken similar measures, mostly based 
on the use of only, or preferentially, plasma from male donors for single-donor plasma 
and platelet concentrates. These policies resulted in up to a two-third reduction in TRALI 
cases. In our meta-analysis of all trials on low-risk TRALI donor strategies we found that 
that these precautionary measures indeed reduced the risk of TRALI (OR 0.61, 95%CI 
0.42-0.86). The effect was most clear in at-risk patient populations (OR 0.51, 95%CI, 
0.29-0.90). These results were confirmed in another recent meta-analysis.26 Schmickl et 
al found that a male-predominant plasma transfusion policy reduces plasma-related 
TRALI incidence by 73% (95% CI, 62-80%). These precautionary measures are effective in 
minimizing the risk of antibody-mediated TRALI, but it can have serious consequences 
for the blood supply by deferral of half of the potential plasma donors. To overcome this 
problem of shortage of donors some blood collection organizations screen all donors 
(or all female donors) for WBC-reactive antibodies. Donors who test positive for these an-
tibodies are excluded for donations. Some countries use pooled solvent/detergent (S/D) 
plasma instead of single donor plasma, claiming that TRALI reactions are not associated 
with S/D plasma. In 2014 the national blood supply organization in the Netherlands has 
introduced S/D plasma instead of fresh frozen plasma. In the next years we will learn 
whether this will lead to a further decrease in the incidence of TRALI caused by plasma.
Most countries implemented the male-only donor strategies for fresh frozen plasma. 
Some blood collection organizations (e.g in the Netherlands) also implemented a male-
only donor strategy for other high-volume plasma products such as platelet concen-
trates.24 In our case-referent study we found that the risk of TRALI was not increased 
among recipients of plasma-poor products (e.g. RBCs) from female donors. Although it is 
known that WBC-reactive antibodies present in RBC transfusions can cause TRALI12,28 our 
study suggests that a male only policy for plasma-poor products is not rational
future directions
The implementation of male-only plasma donor strategies has reduced the incidence of 
antibody-mediated TRALI, but did not totally prevent this serious transfusion reaction. 
First of all not all countries changed to a male only plasma policy for all high volume 
plasma products (e.g. pooled platelets). Second approximately 1% of the currently used 
male donor population for high volume plasma products have WBC-reactive antibod-
ies.10 Third, not in all countries male donors who had a blood transfusion themselves are 
excluded from donating blood. And fourth, as mentioned before, plasma poor products 
such as RBC’s contain a mean volume of 10-20 mL plasma and can cause TRALI.12,25 Also 
some countries use a preferentially male-only donor policy for FFP, meaning that some 
FFPs still are derived from female donors, mainly AB plasma. To completely minimize 
the risk of antibody-mediated TRALI, all donors should be screened for WBC-reactive 
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antibodies and positive donors should be excluded for all plasma containing blood 
products, regardless of the amount of plasma.
Occurrence of non-antibody mediated TRALI is not influenced by these measures. 
Accumulation of bioactive substances are thought to contribute to the occurrence of 
TRALI.29-30 Storage time and storage conditions may contribute to the development of 
these bioactive substances with neutrophil priming ability. However these studies are 
based on pre-clinical data and observational clinical studies. Pre-clinical (animal model) 
studies show a clear relation between TRALI and increased storage time of cellular blood 
products.30-32 Observational studies however report conflicting results.33 This may be 
explained by the heterogeneity of the studies, patients differed in the severity of the 
first hit and the number of blood products received. Receiving a high number of blood 
products, raises the chance of receiving “old” blood products. Also patients who receive 
many transfusions generally are critically ill. Prospective randomized studies are needed 
to elucidate the factors in non-antibody mediated TRALI.
There is no specific treatment for TRALI, management of TRALI is supportive. Once 
TRALI occurs it causes high morbidity and mortality. In patients who require mechanical 
ventilation a low tidal volume strategy is recommended.34 A restrictive transfusion policy 
reduces adverse transfusion reactions (e.g. TRALI) and has been proven to be save in the 
majority of patient populations.35 Clinicians should be made more aware of the risks of 
blood transfusions and the importance to apply to restrictive transfusion policies.
In conclusion, most TRALI cases are thought to be caused by WBC-reactive antibodies. 
The implementation of low-risk TRALI donor strategies for high volume plasma blood 
products, has significantly reduced TRALI risk. Futures research should be focused on 
the pathophysiology of non-antibody mediated TRALI, the standardization of antibody 
screening assays for antibody mediated TRALI and therapeutic strategies for TRALI in 
general. Also clinicians should be made more aware of the risk of blood transfusions.
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Bloedtransfusie is niet meer weg te denken uit de moderne geneeskunde. Het wordt 
gezien als een levensreddende handeling. De afgelopen jaren is het echter duidelijk 
geworden dat het ook een potentieel levensbedreigende interventie is. Transfusiege-
relateerde acute longschade (TRALI) is daarbij de meest voorkomende oorzaak van 
transfusie geassocieerde mortaliteit. TRALI werd eerder gezien als een zeldzame bijwer-
king van transfusie geneeskunde, recente studies laten zien dat tot wel 1 op 10 hoog 
risico patiënten die een transfusie ontvangt TRALI ontwikkelt. De meerderheid van de 
TRALI gevallen, tot wel 89%, wordt gedacht te worden veroorzaakt door de passieve 
infusie van antistoffen die aanwezig zijn in plasma-bevattende bloedproducten. Deze 
donorantistoffen zijn gericht tegen de antigenen van de ontvanger en zorgen voor 
activatie van de witte bloedcellen. Deze activatie leidt tot schade aan de longcapillairen 
met als gevolg lekkage van eiwitten en vocht vanuit de capillairen naar de longblaasjes 
(longoedeem). Dit resulteert uiteindelijk in acute benauwdheid bij de patiënt oftewel 
TRALI. Dit proefschrift richt zich op de rol van donorantistoffen bij het optreden van 
TRALI. Daarnaast wordt er ook gekeken naar preventieve maatregelen om het optreden 
van TRALI te verminderen.
Hoofdstuk 2 beschrijft een observationele studie van alle gerapporteerde TRALI 
gevallen die voldeden aan de Canadese consensus conferentie criteria voor TRALI in 
Nederland gedurende een periode van 2.5 jaar (januari 2005 tot juli 2007). In totaal 
voldeden 49 patiënten aan alle criteria voor TRALI. Klinische en laboratorium kenmer-
ken van deze gevallen werden beschreven. Alle patiënten en betrokken donors werden 
onderzocht op antistoffen gericht tegen witte bloedcellen (HLA klasse I en II en granu-
locyten antistoffen). Er was een hoge morbiditeit en mortaliteit onder de patienten die 
TRALI ontwikkelden. Achtenzeventig procent van de patiënten werd opgenomen op de 
intensieve zorg afdeling en een gedeelte had daarbij mechanische beademing nodig. In 
totaal overleden 10 patiënten. Hoog-volume plasma producten (vers ingevroren plasma 
[FFP] en/of bloedplaatjes in plasma) waren betrokken bij 61% van de TRALI gevallen. De 
overige gevallen van TRALI kregen alleen rode bloedcellen toegediend. In 73% van de 
TRALI gevallen werd er bij één of meer betrokken donors antistoffen gericht tegen witte 
bloedcellen gevonden. Hierbij was er sprake van bewezen incompatibiliteit bij 21/44 
(48%) van de onderzochte gevallen. TRALI gevallen waarbij bewezen onverenigbaarheid 
van antistof en antigeen tussen patiënt en donorbloed is aangetoond noemen we anti-
stof-gemedieerde TRALI. Mogelijke TRALI gevallen (aanwezigheid van een alternatieve 
risicofactor voor acute longschade) hadden een significant lager incompatibiliteits per-
centage vergeleken met TRALI gevallen, 18% versus 58%. Bij de 21 antistof gemedieerde 
TRALI gevallen werden in totaal 31 donors met antistoffen gevonden. FFP producten 
afkomstig van vrouwelijke donoren waren betrokken bij 57% van de bewezen antistof 
gemedieerde TRALI gevallen. Deze TRALI gevallen hadden theoretisch voorkomen kun-
nen worden door het gebruik van plasma afkomstig van mannelijke donoren.
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In het algemeen wordt aangenomen dat de meerderheid van de TRALI gevallen wordt 
veroorzaakt door vrouwelijke donoren. In hoofdstuk 3 hebben we de relatie tussen 
vrouwelijke donoren en het optreden van TRALI onderzocht in een internationale, mul-
ticenter case-referent studie. TRALI patiënten die bloedproducten ontvingen afkomstig 
van donoren van 1 sekse werden vergeleken met een referentie populatie. De geobser-
veerde sekse verdeling onder donoren van deze TRALI patiënten werd vergeleken met 
de verwachte sekse verdeling. Er werden drieëntachtig TRALI patiënten geïncludeerd 
die transfusies ontvingen van uniseks donoren. Het relatieve risico (RR) op TRALI na een 
transfusie van vrouwelijke rode bloedcel producten was 1.2 (95% betrouwbaarheidsin-
terval [CI] 0.69-2.1). Onder ontvangers van plasma-rijke bloedproducten was het RR 19 
(95% CI 1.9-191). Dit duidt erop dat de rol van vrouwelijks donoren in TRALI gevallen 
veroorzaakt door rode bloedcel producten verwaarloosbaar is.
Antistoffen gericht tegen witte bloedcellen worden voornamelijk gevonden in do-
noren die zijn blootgesteld aan lichaamsvreemde antigenen. Deze antistoffen kunnen 
gevormd worden door blootstelling van het immuunsysteem aan lichaamsvreemde 
cellen of weefsels (bijvoorbeeld door zwangerschap, bloedtransfusie of transplantatie). 
In hoofdstuk 4 onderzochten we de bijdrage van aan lichaamsvreemde antigenen 
blootgestelde donoren aan het optreden van TRALI veroorzaakt door plasma-arme en 
plasma-rijke bloedproducten. We hebben een case-referent studie uitgevoerd waarbij 
gegevens over de blootstelling aan lichaamsvreemde antigenen van alle 223 donors 
betrokken bij TRALI gevallen werden vergeleken met informatie over deze blootstel-
ling in de totale donorpopulatie (de verwachte blootstelling). Eenenvijftig procent van 
alle TRALI gevallen had mogelijk voorkomen kunnen worden door uitsluiten van aan 
lichaamsvreemde antigenen geëxposeerde donoren. Bij de 19 patiënten die alleen 
plasma-arme bloedproducten ontvingen was blootstelling aan allogene antigenen niet 
geassocieerd met TRALI. Concluderend, donoren die blootgesteld zijn aan lichaams-
vreemde antigenen geven een verhoogd risico op TRALI bij ontvangers van plasma-rijke 
bloedproducten, maar niet bij ontvangers van plasma-arme producten.
Om de diagnose antistof-gemedieerde TRALI te ondersteunen, worden betrokken 
donors onderzocht op antistoffen gericht tegen witte bloedcellen. Identificatie van 
antistof-positieve donoren is belangrijk, aangezien exclusie van deze donoren onder-
deel is van strategieën ter preventie van TRALI. In hoofdstuk 5 hebben we onderzocht of 
het gebruik van bead-based technieken bij het opsporen van antistoffen het stellen van 
de diagnose antistof-gemedieerde TRALI zou verbeteren. In een serie van 91 achtereen-
volgend gemelde TRALI gevallen die allen voldeden aan de Canadese consensus con-
ferentie criteria werden cellular-based testen vergeleken met bead-based technieken. 
Bij bead-based technieken wordt gebruik gemaakt van bolletjes (“beads”) bedekt met 
antigenen, terwijl bij cellular-based technieken gebruik wordt gemaakt van verse witte 
bloedcellen. Bij 113 donoren werden HLA antistoffen gevonden, waarvan er 84 alleen 
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werden gevonden met bead-based technieken, 12 alleen met cellular-based testen en 
17 in beide technieken. Antistof-gemedieerde TRALI werd gediagnostiseerd bij 44/91 
(48%) van de gerapporteerde gevallen. Eenentwintig van deze antistof-gemedieerde 
gevallen zouden niet zijn aangetoond bij het gebruik van alleen cellular-based testen. 
De resultaten van deze studie laten zien dat bead-based technieken een hogere ge-
voeligheid hebben voor het ontdekken van onverenigbare donoren bij TRALI gevallen 
ten opzichte van cellular-based testen. Deze resultaten suggeren dat het gebruik van 
bead-based technieken mogelijk zal resulteren in een afname van toekomstige TRALI 
gevallen, aangezien meer donoren met antistoffen tegen witte bloedcellen zullen wor-
den uitgesloten van donaties.
Antistof-gemedieerde TRALI is het meest voorkomende type van TRALI. Antistoffen 
gericht tegen witte bloedcellen worden voornamelijk gevonden bij vrouwelijk donoren 
die ooit zwanger zijn geweest. Plasma afkomstig van mannelijke donoren zou dus een 
lagere risico op TRALI moeten geven dan plasma van vrouwelijke donoren. Het laatste 
decennium hebben bloedbanken laag-risico donor strategieën toegepast om het optre-
den van TRALI te voorkomen. De meeste strategieën zijn gebaseerd op het gebruik van 
alleen, of bij voorkeur, plasma afkomstig van mannelijke donoren. In hoofdstuk 6 werd 
een systematisch review en meta-analyse verricht om het bewijs voor deze preventieve 
strategieën te bekrachtigen. Tien artikels werden gebruikt voor de meta-analyse. Het 
invoeren van laag-risico donor strategieën verminderde de kans op TRALI. Analyse van 
subgroepen toonde dat dit effect het meest duidelijk was in patiëntenpopulaties die 
meer vatbaar zijn voor het ontwikkelen van TRALI, bijvoorbeeld kritiek zieke patiënten 
op de intensieve zorg afdeling en patiënten na grote operaties.
Dit proefschrift laat zien dat donorantistoffen een centrale rol spelen in het optreden 
van TRALI. Producten afkomstig van vrouwelijk donoren die één of meerdere keren 
zwanger zijn geweest vormen een verhoogd risico op het ontstaan van TRALI, met 
name hoog-volume plasma producten (vers ingevroren plasma en/of bloedplaatjes in 
plasma). Het onderbouwen van antistof-gemedieerde TRALI middels laboratorium di-
agnostiek kan het best gebeuren middels bead-based technieken. Een belangrijke stap 
in het voorkomen van TRALI is het invoeren van laag-risico donor strategieën, waarbij 
hoog-volume plasma producten alleen, of bij voorkeur, afkomstig zijn van mannelijke 
donoren.
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Eindelijk is mijn proefschrift af, het is letterlijk een tienjarenplan geworden! Graag wil ik 
iedereen bedanken die direct, of indirect, een bijdrage heeft geleverd aan mijn promotie 
onderzoek.
Als eerste mijn promotor Prof. dr. van Rhenen, beste Dick, hartelijk dank dat je mij 10 
jaar geleden de kans hebt geboden om onderzoek te komen doen bij de bloedbank. Je 
was ondanks je drukke werkzaamheden altijd bereikbaar en snel met het leveren van 
commentaar op mijn manuscripten. Onderzoek doen kent pieken en dalen. Ondanks 
dat mijn onderzoek een aantal jaren op een laag pitje heeft gestaan, heb je mij toch de 
mogelijkheid geboden om het af te ronden.
Mijn dank gaat ook uit naar mijn beide copromotoren, dr. E.A.M. Beckers en dr. A.P.J. 
Vlaar.
Beste Erik, bedankt voor je enthousiaste begeleiding, ideeën, betrokkenheid en natuur-
lijke gezellige congressen tijdens de eerste jaren van mijn onderzoek.
Beste Alexander, dankzij jou is mijn onderzoek nieuw leven ingeblazen. Ik sta er steeds 
weer versteld van hoe jij alle ballen in de lucht houdt. Bedankt voor je enthousiasme, 
je supersnelle commentaar op manuscripten en je geduld met mij. Zonder jou zou dit 
boekje er niet zijn gekomen.
Prof. dr. Anneke Brand, je betrokkenheid bij en bijdrage aan mijn onderzoek heb ik altijd 
zeer gewaardeerd. Hartelijk dank voor de snelle beoordeling van mijn proefschrift en 
het plaats nemen in mijn kleine commissie.
Prof. dr. Jan van Saase, destijds attendeerde u mij op het promotieonderzoek bij de San-
quin bloedbank. Hierna gaf u mij de mogelijkheid in opleiding te gaan voor de interne 
geneeskunde. Hartelijk dank dat u nu plaats wilt nemen in mijn kleine commissie.
Prof. dr. Frank Leebeek, mijn eerste onderzoekservaring heb ik onder jouw enthousiaste 
begeleiding opgedaan tijdens mijn afstudeeronderzoek. Dit resulteerde in mijn eerste 
paper! Ik vind het dan ook erg leuk dat je zitting hebt in mijn kleine commissie.
Ook de overige commissieleden, Prof. dr. J. J. Zwaginga en Prof dr. C.E. van der Schoot, 
wil ik hartelijk danken voor het plaatsnemen in mijn commissie.
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Ik wil hier tevens alle betrokken artsen en hemovigilatie-medewerkers bedanken die 
TRALI-gevallen gemeld hebben en klinische gegevens verzameld hebben. Michaela van 
Bohemen, dank voor alle (gezellige) uren die wij samen tussen de statussen en achter 
Elpado hebben doorgebracht!
Alle laboranten van het voormalige “rode en witte” lab in Dordrecht wil ik bedanken voor 
alle gezellige koffiepauzes, lunches, lab-uitjes en Sinterklaas vieringen. Ondanks dat ik 
officieel niet bij jullie hoorde, werd ik volledig door jullie in de groep opgenomen.
Dr. Kees Sintnicolaas en dr. Wilfried Levering; dank voor het uitvoeren van de “bead-
based” assays en het beantwoorden van mijn vele vragen over de diagnostiek.
Dr. Leendert Porcelijn en dr. Junior Lardy, dank voor het verrichten van de TRALI-
diagnostiek en de snelle reacties op manuscripten. Het was soms een hele operatie om 
het verse bloed op tijd in Amsterdam te krijgen!
Jacques Wollersheim en Fikreta Danovic, dank voor alle hulp bij het verzamelen van 
de TRALI-patiënten in de regio’s zuidoost en noordwest. Tevens dank aan alle andere 
artsen van de klinisch consultatieve dienst van Sanquin voor hun hulp bij de inclusie van 
patiënten en de donorartsen voor het oproepen van alle betrokken donoren.
Alle co-auteurs wil ik bedanken voor hun bijdrage aan mijn manuscripten.
Ook al mijn klinische collega’s gedurende de jaren in het Ikazia Ziekenhuis, Erasmus MC 
en het LUMC wil ik bedanken voor de leuke en leerzame tijd.
Op 11 september zal ik worden bijgestaan door twee goede vriendinnen. Lieve Nathalie, 
alweer 20 jaar geleden (wat gaat de tijd toch snel…) leerden wij elkaar tijdens de studie 
kennen bij studievaardigheden. Later werden we huisgenoten. We hebben heel wat 
leuke vakanties samen gehad, met als hoogtepunt onze Amerika-reis. Ik ben blij dat je 
straks naast mij staat! Lieve Janneke, na jullie verhuizing van België naar Barendrecht 
werden wij vriendinnen, 6 jaar geleden mocht ik getuige zijn bij jouw huwelijk. Nu sta jij 
straks naast mij bij mijn promotie.
Annemarie en Arnim, met veel plezier kijk ik terug op onze wintersportvakanties, hope-
lijk volgen er de komende jaren nog meer!
Renate, we zien elkaar tegenwoordig wat minder vaak, maar als we elkaar zien is het 
weer als vanouds. Dank voor je vriendschap! Wendy, ik hoop de komende jaren nog vaak 
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met je op congres te gaan (en met de jongens af te spreken) en houd me aanbevolen 
voor onze duo-baan!
Lieve Edwin en Adelinde, Henny, Nelly, Claudia en Marco, dank voor jullie interesse en 
steun.
Lieve pap en mam, dank voor al jullie steun de afgelopen jaren! Jullie hebben me altijd 
alle kansen geboden en staan altijd met veel liefde voor ons klaar.
Tenslotte de 3 belangrijkste mannen in mijn leven:
Tim en Sander, jullie brengen zoveel geluk, liefde en plezier in mijn leven. Ik ben er trots 
op jullie moeder te zijn! Ik geniet iedere dag van jullie lieve lachen en ondeugende 
streken. Mijn allerliefste Ron, alweer ruim 10 jaar delen wij lief en leed. Dank voor al je 
liefde, steun en vertrouwen in mij. I will always love you.
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Daniëlle van Stein werd geboren op 7 februari 1977 in Gouda. In 1995 behaalde zij haar 
VWO diploma aan het IJsselcollege in Capelle aan den IJssel. In hetzelfde jaar startte zij 
haar studie geneeskunde aan de Erasmus Universiteit te Rotterdam. In 1999 behaalde zij 
haar doctoraal examen en in 2001 het artsexamen.
Aansluitend werkte zij als arts niet in opleiding tot specialist op de afdeling Interne 
Geneeskunde van het Medisch Centrum Rijnmond-Zuid (nu het Maasstad Ziekenhuis). 
In 2005 startte zij met haar promotie-onderzoek bij de Sanquin Bloedbank in Dordrecht 
onder supervisie van dr. E.A.M. Beckers en prof. dr. D.J. van Rhenen. In latere instan-
tie werd ook dr. A.P.J. Vlaar als co-promoter betrokken bij het onderzoek. Tijdens dit 
onderzoek volgde zij het postinitieel masteronderwijs epidemiologie aan het EMGO 
onderwijsinstituut van het VUmc.
In juni 2008 begon Daniëlle aan de opleiding tot internist in het Ikazia Ziekenhuis te 
Rotterdam (opleider dr. A. Dees). In mei 2011 vervolgde zij haar opleiding in het Erasmus 
MC te Rotterdam (opleider prof. dr. J.L.C.M. van Saase). In september 2013 is zij gestart 
met haar differentiatie Medische Oncologie in het LUMC te Leiden (opleider prof. dr.A.J. 
Gelderblom). Per 1 augustus 2015 is zij geregistreerd als internist.
Daniëlle is getrouwd met Ron en samen hebben zij twee zoons, Tim en Sander.
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van stein d, Beckers EA, Peters A-L, Porcelijn L, Middelburg RA, Lardy NM, van Rhenen 
DJ, Vlaar AP. Underdiagnosing of antibody mediated transfusion-related acute lung 
injury: evaluation of cellular-based versus bead-based techniques. Submitted.
Peters A-L, van stein d, Vlaar AP. Antibody-mediated transfusion-related acute lung 
injury; from discovery to prevention. Br J Haemat. 2015 Apr 28. doi: 10.1111/bjh.13459. 
[Epub ahead of print]
van stein d*, Muller MC*, Binnekade JM, van Rhenen DJ, Vlaar AP. Low-risk transfusion-
related acute lung injury donor strategies and the impact on the onset of transfusion-
related acute lung injury: a meta-analysis. Transfusion. 2015;55:164-75.
*Both authors contributed equally to the manuscript
Middelburg RA, van stein d, Atsma F, Wiersum-Osselton JC, Porcelijn L, Beckers EA, Briët 
E, van der Bom JG. Alloexposed blood donors and transfusion-related acute lung injury: 
a case-referent study. Transfusion. 2011;51:2111-7.
Middelburg RA, van stein d, Zupanska B, Uhrynowska M, Gajic O, Múniz-Diaz E, Galvez 
NN, Silliman CC, Krusius T, Wallis JP, Vandenbroucke JP, Briët E, van der Bom JG. Female 
donors and transfusion-related acute lung injury: A case-referent study from the Inter-
national TRALI Unisex Research Group. Transfusion. 2010;50:2447-54.
Vlaar AP, Binnekade JM, Prins D, van stein d, Hofstra JJ, Schultz MJ, Juffermans NP. Risk 
factors and outcome of transfusion-related acute lung injury in the critically ill: a nested 
case-control stud. Crit Care Med. 2010;38:771-8.
van stein d, Beckers EA, Sintnicolaas K, Porcelijn L, Danovic F, Wollersheim JA, Brand 
A, van Rhenen DJ. Transfusion-related acute lung injury reports in the Netherlands: an 
observational study. Transfusion. 2010;50:213-20.
Wiersum-Osselton JC, Porcelijn L, van stein d, Vlaar AP, Beckers EA, Schipperus MR. 
Transfusion-related acute lung injury (TRALI) in the Netherlands in 2002-2005. Ned 
Tijdschr Geneeskd. 2008;152:1784-8.
Middelburg RA, van stein d, Briët E, van der Bom JG. The role of donor antibodies in the 
pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion. 
2008;48:2167-76.
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Leebeek FW, Stadhouders NA, van stein d, Gómez-García EB, Kappers-Klunne MC. 
Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol. 
2001;67:15-9.
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summary of Phd training and teaching
year workload
general courses
- Epidemiologisch onderzoek: opzet en interpretatie, EMGO 2005 4 ECTS
- Inleiding SPSS, EMGO 2006 0.5 ECTS
- Principes van epidemiologische data-analyse, EMGO 2006 3 ECTS
- Lineaire regressie en variantie-analyse, EMGO 2006 3 ECTS
- Logistische regressie en analyse van overlevingsduren, EMGO 2006 3 ECTS
- Doelmatigheidsonderzoek: methoden en principes, EMGO 2007 2 ECTS
- Toepassingsgebieden van de epidemiologie, EMGO 2007 3 ECTS
- Clinimetrics: assessing measurement properties of health measurement 
instruments, EMGO
2007 3 ECTS
Presentations
- Symposium Regionaal Hemovigilantie Platform Zuidwest, oral presentation 2006 0.3 ECTS
- Sanquin Bloedbankavond, oral presentation 2006 0.2 ECTS
- ISBT Annual Meeting 2006, poster presentation 2006 1 ECTS
- TRIP symposium 2007, poster presentation 2007 0.2 ECTS
- Internistendagen 2008, oral presentation 2008 0.5 ECTS
- ISBT Annual Meeting 2008, oral presentation 2008 1 ECTS
- ISBT Annual Meeting 2010, poster presentation 2010 1 ECTS
(inter)national conferences
- European Symposium on Platelet and Granulocyte Immunobiology, 2006, 
Tromso, Norway
2006 1 ECTS
- ISBT Annual Meeting 2006, Cape Town, South Africa 2006 1 ECTS
- TRIP hemovigilantie symposium 2006, Rotterdam 2006 0.3 ECTS
- Sanquin Spring Seminars 2007, Amsterdam 2007 0.5 ECTS
- ISBT Annual Meeting 2007, Madrid, Spain 2007 1 ECTS
- TRIP hemo- en weefselvigilantie symposium 2007, Utrecht 2007 0.3 ECTS
- Internistendagen 2008, Maastricht 2008 0.5 ECTS
- ISBT Annual Meeting 2008, Macao, China 2008 1 ECTS
- Internistendagen 2009, Maastricht 2009 0.5 ECTS
- Internistendagen 2011, Maastricht 2011 0.5 ECTS
- Internistendagen 2013, Maastricht 2013 0.5 ECTS
- ESMO Annual Meeting 2014, Madrid, Spain 2014 1 ECTS
other
- Research Bespreking Sanquin Bloedbank, Leiden 2005-2008 1 ECTS
- Journal Club Sanquin Bloedbank, Leiden 2005-2008 1 ECTS
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